|

Seqirus mentions - Seqirus Media Monitoring - 19th Feb 2018

    View this newsletter in full

New flu vaccinations to be made available to older Australians, for free in April

Two new, stronger flu vaccines will be available to older Australians for free this season in a bid to prevent another deadly outbreak. More than 1,100 people across Australia died from the flu last year, with most of them over the age of 65. Fluad and FluZone will be free for over 65s when the supply arrives in Australia in April, the federal government announced. “The two new vaccines are about giving Australians the best chance at getting through the flu season with as little impact as possible,” Health Minister Greg Hunt said.
18th Feb 2018 - The West Australian

Stronger flu vaccines available to over-65s this year


19th Feb 2018 - The Australian

Stronger flu vaccine for Aussies over 65


18th Feb 2018 - Newcastle Herald

"Enhanced" flu vaccines made available after last year's "horrific" season left 1000 people dead


18th Feb 2018 - Radio Australia

Seniors to get free flu shots after deadly outbreak last year


18th Feb 2018 - Daily Liberal

Government announces free flu vaccine for three million older Australians


18th Feb 2018 - TenPlay.com.au

New free flu vaccine for over 65s from April


18th Feb 2018 - Perth Now

"Enhanced" flu vaccines made available after last year's "horrific" season left 1,000 people dead


18th Feb 2018 - ABC Open

Stronger flu vaccine for Australians over-65s


18th Feb 2018 - Yahoo7 News

Federal flu vaccine boost to deliver free, stronger shots for over-65s


18th Feb 2018 - 9News.com.au

Seniors to get free flu shots as government reacts to 2017 deaths


18th Feb 2018 - Central Western Daily.com.au

DONE - TAG TO MAIN 1 - Seniors to get free flu shots as government reacts to 2017 deaths


18th Feb 2018 - Western Advocate

DONE - MAIN STORY 1 - Free stronger flu vaccine for older Australians after 2017's deadly outbreak

Older Australians will be given free, stronger flu vaccinations by the federal government in an effort to prevent another deadly outbreak. The stronger vaccine will be delivered in a $31m program. Fluad and FluZone will be free for over 65s when the supply arrives in Australia in April. “We will be making it available free of charge to everybody over the age of 65 because sadly that’s where 95% of those who lost their lives are from in terms of age,” federal health minister Greg Hunt said. “And this is the world’s leading vaccines and in particular we have been able to secure supplies for all Australians that will require it. So I think that’s a real breakthrough.”
18th Feb 2018 - The Guardian

Stronger flu vaccine rolled out for older Aussies


18th Feb 2018 - Yahoo News Australia

Federal flu vaccine boost to deliver free, stronger shots for over-65s


18th Feb 2018 - 9News.com.au

DONE - TAG TO MAIN 1 - Stronger flu vaccine rolled out for older adults


17th Feb 2018 - MSN.com


Seqirus mentions - Seqirus Media Monitoring - 16th Feb 2018

    View this newsletter in full

CSL Provides Trifecta Of Good News

A trifecta of good news from CSL yesterday in its 2017-18 first half report: more sales, more profits and a higher dividend. The company reported that sales of its new quadrivalent vaccines surged 43% in the half, with output from the Holly Springs, North Carolina facility in the US seeing a 400% jump. CEO Paul Perreault said the strong results in the flu vaccine division were because its four-strain flu vaccine product is in high demand with consumers in the Northern Hemisphere flu season.
15th Feb 2018 - Sharecafe.com.au


Seqirus mentions - Seqirus Media Monitoring - 15th Feb 2018

    View this newsletter in full

CSL a 'quiet performer' and is in rude health

CSL continues to surprise on the upside, with a 34 per cent jump in half-year profit, as chief Paul Perreault described the company a “quiet performer”. Mr Perreault outlined in the results that Seqirus had continued to progress as planned. “There was a lot of scepticism of whether we could meet the strategy when we took over the business a couple of years ago and the team has been executing well.” Seqirus recorded a 43 per cent increase in sales of the seasonal influenza vaccine, as a busy flu scene making headlines in Britain, the US and Australia because of the strong strain of the virus.
14th Feb 2018 - Australian

Australia's CSL lifts outlook after H1 profit jump; stock at record high


14th Feb 2018 - Reuters

CSL HY profit at $US1b-plus for first time


14th Feb 2018 - thewest.com.au

Why the CSL Limited share price is up 5% as profits jump 35%


14th Feb 2018 - Motley Fool

CSL Limited up on strong first-half results


14th Feb 2018 - The Pharma Letter

CSL Limited Report Lights Up ASX 200


14th Feb 2018 - Rask Media

News of Note—CSL’s flu vaccine sales, Inovio and more

Among vaccine news of note this week: sales of CSL’s Flucelvax quadrivalent flu vaccine were up 43% for the six months leading up to December. FDA Commissioner Scott Gottlieb, M.D., said his agency is working with the CDC to understand why protection offered by this year’s flu vaccine is less than optimal.
14th Feb 2018 - FiercePharma

Pharmaceutical company CSL Ltd is right on track

CSL Limited, the Australian parent company of CSL Behring, increased earnings by more than 30 percent in 2017. There was also news locally that the construction of the new factory in Lengnau is in full swing. Susanne Jecklin, who was recently confirmed as site manager of the Lengnau plant, sees the construction progress as being right on schedule: "The facade work on all buildings was completed last December. Soon the utilities will be completed too and all work related to the electrical installations will begin.
14th Feb 2018 - Grenchner Tagblatt

Time for tax certainty, says CSL chief

CSL's Paul Perreault has called on the Turnbull government to give scientists greater support and maintain tax incentives for companies investing in R&D if it truly wants to make Australia more innovative. CSL reported its half-year net profit rose 34.9 per cent to $US1.09 billion ($1.39 billion). Mr Perreault said the strong results in the flu vaccine division were driven by its four-strain flu vaccine product which had been in high demand with consumers in the northern hemisphere.
14th Feb 2018 - Sydney Morning Herald

Australia’s largest biotechnology company leading in innovation

CSL CEO Doctor Paul Perreault talks about the importance of innovation in the biotechnology business. He also mentions the company results and the success of the vaccine business Seqirus
14th Feb 2018 - 4bc.com.au


Seqirus mentions - Seqirus Media Monitoring - 14th Feb 2018

    View this newsletter in full

CSL profits get a boost from surging demand for flu vaccines

CSL says sales of its Seqirus seasonal flu vaccines have jumped as people fight tougher strains of the flu virus. Sales of CSL's new quadrivalent vaccines, which help protect against four strains of flu, were up 43 per cent, with output from the Holly Springs, North Carolina facility that CSL acquired from Novartis three years ago, up fourfold. Paul Perreault said the company was working on delivering higher-dose flu vaccines in Australia for high-risk patients.
14th Feb 2018 - Brisbane Times

CSL profits get a boost from surging demand for flu vaccines


14th Feb 2018 - Sydney Morning Herald

CSL boosts dividend, full year guidance after bumper half year


13th Feb 2018 - Australian Financial Review

CSL: 1st Half Profit Rises 35% on Immunoglobulin, Flu-Vaccine Sales


13th Feb 2018 - 4-Traders

CDC Still Recommends Sanofi, GlaxoSmithKline Vaccines As Flu-Related Deaths Rise

The lethal H3N2 flu strain and comorbid diseases claimed at least 4,000 lives in the U.S. last week, according to the CDC. Only Seqirus and Sanofi are known to produce vaccines that effectively inhibit H3N2, but the CDC also recommended products from GlaxoSmithKline. AstraZeneca's FluMist was not prescribed this year. Considering the demand for vaccines this season, the pharmaceutical companies might have incentive to invest in research and development for more potent, comprehensive products.
12th Feb 2018 - Yahoo Finance

Big Pharma is thriving off the flu: Business is booming as thousands Americans die each week from this year's historic pandemic

As the flu pandemic is killing and sickening scores of Americans, Big Pharma companies' profits are soaring. There are five companies that make flu shots recommended by the CDC this year: Seqirus, GlaxoSmithKline, Sanofi Pasteur and Protein Sciences. For a private sector customer, a flu shot costs between $15.64 and $21.12 per dose, according to the CDC. The largest out of those five companies, Sanofi Pasteur and GlaxoSmithKline made some very serious bucks on their vaccines in 2017, especially in the fourth financial quarter of the year, as the flu was really ramping up in the US.
12th Feb 2018 - Daily Mail

New Anti-Flu Drugs To Combat Viral Mutations Using Alternative Mechanisms

Nearly all anti-flu drugs work the same way. Tamiflu, Relenza, Rapivab, and Inavir inhibit the function of neuraminidase, an enzyme that allows germs to spread the infection from one cell to another. Baloxavir, an experimental drug by Shionogi, could be available for release in Japan this March. However, it won't reach U.S. shores until 2019. Unlike Tamiflu, the medication works by blocking the activity of the protein the influenza virus needs to create copies of itself. All a patient needs is a single dose.
12th Feb 2018 - Tech Times


Seqirus mentions - Seqirus Media Monitoring - 13th Feb 2018

    View this newsletter in full

CDC Still Recommends Sanofi, GlaxoSmithKline Vaccines As Flu-Related Deaths Rise

The lethal H3N2 flu strain and comorbid diseases claimed at least 4,000 lives in the U.S. last week, according to the CDC. Only Seqirus and Sanofi are known to produce vaccines that effectively inhibit H3N2, but the CDC also recommended products from GlaxoSmithKline. AstraZeneca’s FluMist was not prescribed this year. Considering the demand for vaccines this season, the pharmaceutical companies might have incentive to invest in research and development for more potent, comprehensive products.
12th Feb 2018 - Benzinga

As raging flu epidemic spreads, Sanofi Pasteur targets more effective cell-based universal vaccine

Sanofi Pasteur has signed a deal with SK Chemicals to license cell culture vaccine technology as the raging flu epidemic in the U.S., one of the worst in recent history, highlights the need for a universal vaccine and more potent flu shots produced in cells instead of eggs. Currently Seqirus, which sells Flucelvax, has the only FDA-approved mammalian cell-based flu shot.
12th Feb 2018 - FiercePharma

Treating the Flu in Just 24 Hours

People may soon have another option when treating the flu. And, this new single-dose medicine could work in just 24 hours. This is important since rare sporadic instances of oseltamivir-resistant and peramivir-resistant influenza A(H1N1)pdm09 viruses and oseltamivir-resistant influenza A(H3N2) viruses have been detected worldwide. Shionogi completed a phase 3 clinical trial in January 2018, for Baloxavir marboxil, a medication that is reported to kill the flu virus within one day
12th Feb 2018 - Precision Vaccinations


Seqirus mentions - Seqirus Media Monitoring - 12th Feb 2018

    View this newsletter in full

New flu vaccine guidance for 2018–2019 winter season

For the 2018–2019 winter season in England, GP practices and pharmacy contractors should offer the adjuvanted trivalent vaccine (aTIV) for all patients aged 65 years and over, and the quadrivalent vaccine (QIV) for people aged 18 to 65 years in at-risk groups, according to guidance from NHS England and Public Health England.
10th Feb 2018 - The Pharmaceutical Journal


Seqirus mentions - Seqirus Media Monitoring - 9th Feb 2018

    View this newsletter in full

High-strength flu vax for over-65s likely to be added to immunisation program

In Australia, a high-strength flu vaccine for over-65s is likely to be added to the National Immunisation Program next month to prevent a repeat of last year’s ‘horror season’. While submissions to fund Fluzone will go before the PBAC for formal approval in March, Australian Doctor has learned that its manufacturer, Sanofi, has already increased production of the vaccines to ensure they are available for the start of the flu season. The PBAC is also examining a submission for the trivalent Fluad (Seqirus) for 65s and over.
8th Feb 2018 - Pharmacy News

New super vaccine to help elderly fend off flu


8th Feb 2018 - 9News.com.au

New flu jab announced for next winter

GPs and pharmacists in England are being advised to order a different type of flu vaccine ahead of next winter. An adjuvanted trivalent vaccine called Fluad has been shown to boost immunity in adults aged 65 and over. The vaccine was not available for this winter because it was only approved for UK use last summer.
8th Feb 2018 - WebMD


Seqirus mentions - Seqirus Media Monitoring - 8th Feb 2018

    View this newsletter in full

GPs are told to amend flu vaccine orders for next season

For the next flu season, NHS England has told GPs to ensure that they order the quadrivalent vaccine for people aged 18 to 65 who are at risk and the newly licensed adjuvanted trivalent vaccine, Fluad, for patients aged over 65. The letter, from NHS England and Public Health England, advises GPs and community pharmacy contractors to review any orders already made for the 2018-19 season and amend them if necessary. Suppliers have extended the deadline for orders until the end of March, and NHS England has confirmed that additional funding will be available in 2018-19 to support the use of adjuvanted trivalent vaccine and quadrivalent flu vaccine.
7th Feb 2018 - British Medical Journal

GP practices to be funded to order two types of flu vaccines for next winter


8th Feb 2018 - Nursing in Practice

Practices told to order new influenza vaccine for older patients ahead of next winter


7th Feb 2018 - Nursing Times

Flu vaccine: people over 65 years of age to be offered booster jab for the 2018-19 season


7th Feb 2018 - Nursing Standard

GPs advised on flu vaccines for 2018/19 as NHS promises extra funds


6th Feb 2018 - GP Online

Final guidance on flu vaccine ordering for 2018/19 – action required by contractors


6th Feb 2018 - Pharmaceutical Services Negotiating Committee

GPs told to use more expensive flu jab to avoid a repeat of this winter’s outbreak – the worst in seven years

GPs have been told to use a pricier but more effective flu jab to prevent a repeat of this winter’s epidemic. The outbreak was exacerbated as doctors had been strongly encouraged by health trusts to give patients a cheaper vaccine. NHS England and Public Health England have told doctors and pharmacists to ensure that they use the four-strain vaccine to ensure patients get ‘gold standard protection’ next winter. It comes after they admitted the current flu jab is ineffective for over-75s and ordered GPs to switch to a new version called Fluad.
6th Feb 2018 - Daily Mail

NHS bosses telling GPs to use cut-price flu jabs ‘worsened crisis’


7th Feb 2018 - The Sun

New "Immune-Boosting" Flu Jab Will Be Offered Next Winter, Here's What You Need To Know


7th Feb 2018 - Huffington Post UK

Battle of the Flu Shots

Last fall some people in the know about influenza science got picky when it came time to get their flu shots. `My colleagues who are over age 65, everybody wanted basically the Fluad or the Protein Sciences vaccine, Flublok,` said Dr. Michael Osterholm, director of the Center for Infectious Diseases Research and Policy at the University of Minnesota. The proliferation of products has left some people wondering whether public health officials should do more to steer flu vaccine consumers towards Vaccine X or Vaccine Y.
6th Feb 2018 - Medpage Today


Seqirus mentions - Seqirus Media Monitoring - 7th Feb 2018

    View this newsletter in full

LPC worried lack of choice will cause shortage next flu season

A LPC CEO has raised concerns that NHS England is "putting all its eggs" in one basket by relying on one supplier for its recommended flu vaccine for the 2018-19 season. The adjuvanted trivalent vaccine (aTIV) is “now the best option for all 65s and over”, while the quadrivalent vaccine (QIV) is “the best option for 18-65 at-risk groups”, according to the letter by NHS England. City and Hackney local pharmaceutical committee (LPC) CEO Hitesh Patel raised concerns on Twitter that there could be “very little” of the vaccines available, as there is currently only one manufacturer for the aTIV – Seqirus – and just two manufacturers – Mylan and Sanofi Pasteur – supplying QIV.
6th Feb 2018 - Chemist+Druggist

GPs to be funded to order two types of flu vaccines for next winter

NHS England has advised GPs to offer two different types of the flu vaccine for the 2018/19 season, after telling GPs to halt all orders. In a letter, NHS England has told practices and pharmacies to offer the adjuvanted trivalent vaccine (aTIV) for all 65s and over and the quadrivalent vaccine (QIV) for at-risk patients between the ages of 18 and 64. It said it will fund local commissioners to pass on to practices to order both types of vaccine.
6th Feb 2018 - Pulse Today

NHS to offer 'gold standard' flu jabs next year amid concern over failings

In England, the NHS will offer stronger flu jabs next year amid concern that this year’s vaccinations have failed to work effectively. Health officials said the public could expect “gold standard” protection from next winter, in a bid to cut death rates from flu. From next year, pensioners will receive a new type of jab designed to boost their immune response, after the vaccine last year was found to have zero effectiveness. Suppliers have confirmed that there will be enough adjuvanted trivalent vaccine and quadrivalent influenza vaccine to meet demand.
6th Feb 2018 - Daily Telegraph

Over 65s to be offered new flu jab next year, health officials say


6th Feb 2018 - BT.com

Over 65s to be offered new flu jab next year, health officials say


6th Feb 2018 - Daily Mail

Some flu vaccines may work better than others — but guidance to the public is scant

Last fall some people in the know about influenza science got picky when it came time to get their flu shots. “My colleagues who are over age 65, everybody wanted basically the Fluad or the Protein Sciences vaccine, Flublok,” said Dr. Michael Osterholm, director of the Center for Infectious Diseases Research and Policy at the University of Minnesota. The proliferation of products has left some people wondering whether public health officials should do more to steer flu vaccine consumers towards Vaccine X or Vaccine Y.
6th Feb 2018 - STAT

Some flu vaccines may work better than others, but public could use better guidance


6th Feb 2018 - Fox News

NHS to use new type of flu jab next winter

Doctors in England are being asked to order a different type of flu vaccine in time for next winter. NHS England says over-65s should be offered a newly licensed jab called Fluad, which experts say should give better immunity to this age group. NHS England said there would be additional funding available in 2018-19 for the "highly cost-effective" recommended vaccines.
6th Feb 2018 - BBC

NHS England moves to clear up flu vaccine confusion

NHS England has moved to try to clear up confusion over flu vaccines for next winter, following concerns that a better approach last year could have reduced pressure in hospitals.
6th Feb 2018 - Health Service Journal


Seqirus mentions - Seqirus Media Monitoring - 6th Feb 2018

    View this newsletter in full

CDC Flu Update: Pediatric Flu-Related Deaths Continue

In the U.S., influenza activity increased again according to the latest FluView report from the CDC. All U.S. states but Hawaii and Oregon continue to report widespread flu activity. Since October 1, 2017, CDC has tested 282 influenza A(H1N1)pdm09, 828 influenza A(H3N2), and 337 influenza B viruses for resistance to antiviral medications. While the majority of the tested viruses showed susceptibility to the antiviral drugs, two (0.7%) H1N1pdm09 viruses were resistant to both oseltamivir and peramivir, but was sensitive to zanamivir.
5th Feb 2018 - Infection Control Today


Seqirus mentions - Seqirus Media Monitoring - 2nd Feb 2018

    View this newsletter in full

GP practices told to freeze flu vaccine orders until further notice

GP practices have been instructed by NHS England to halt all orders on flu vaccines until February, until all clinical evidence and cost-effectiveness data are re-evaluated. The letter states that ‘no further orders for influenza vaccine should be made and no provisional orders should be converted to confirmed’ until they have released definitive guidance, expected on 5 February. This news follows an earlier letter from NHS England in December 2017 advising GP practices to order two different variations, including Fluad, an adjuvanted vaccine, which they said should be given to over-75s in the 2018/19 flu season.
1st Feb 2018 - Nursing in Practice

PHE supports use of trivalent flu vaccine in older people to reduce hospitalisations

New Public Health England guidance supports the use of the adjuvanted trivalent influenza vaccine in older people saying that it would lead to large reductions in GP consultations and hospitalisations. Priority for the aTIV should be for those aged 75 years and above, but the vaccine would also be effective and cost-effective in those aged 65–74 years. The guidance states: “Trivalent adjuvanted vaccine is a more appropriate choice than standard quadrivalent vaccine for older people.”
1st Feb 2018 - Pharmaceutical Journal


Seqirus mentions - Seqirus Media Monitoring - 1st Feb 2018

    View this newsletter in full

GPs told to freeze all flu vaccine orders until further notice

GPs have been instructed by NHS England to halt all orders on flu vaccines until February, until all clinical evidence and cost-effectiveness data are re-evaluated. The letter states that ‘no further orders for influenza vaccine should be made and no provisional orders should be converted to confirmed’ until they have released definitive guidance, expected on 5 February. This news follows an earlier letter from NHS England in December 2017 advising GP practices to order two different variations, including Fluad, which they said should be given to over-75s in the 2018/19 flu season.
31st Jan 2018 - Pulse Today


Seqirus mentions - Seqirus Media Monitoring - 31st Jan 2018

    View this newsletter in full

Seqirus Early Bird offer for flu Vaccine Extended

Approved supplier of the adjuvanted trivalent flu vaccine Seqirus, have extended their early bird offer till Friday 16 February 2018. This follows a letter sent by NHS England on 22 December advising all GP Practices to use the adjuvanted trivalent vaccine for their 65-75 demographic. Seqirus’ manufacturing plant in Liverpool is now solely dedicated to the manufacture and supply of FLUAD and AGRIPPAL and has ample capacity to supply the UK market.
29th Jan 2018 - LMC Buying Groups


Seqirus mentions - Seqirus Media Monitoring - 30th Jan 2018

    View this newsletter in full

Michigan's flu season is yet to peak — and the vaccine isn't helping much

In Michigan, the flu season has yet even to peak, according to an early review of data at the University of Michigan, one of five sites nationwide where researchers monitor influenza rates. Dr. Arnold Monto, a professor of epidemiology at the U-M School of Public Health in Ann Arbor, is 84, and was immunised with FLUAD. He is a fan of FLUAD and, like most public-health advocates, he said it’s still not too late for seniors or anyone else to get a flu vaccine this season
29th Jan 2018 - Detroit Free Press

CSL Limited hits new record highs

Shares in CSL have hit a new record high of $150.11 in morning trade. Bullish sentiment surrounding CSL has arisen from a number of factors, including the fact that a severe flu outbreak in the U.S. has seen Seqirus increase its share of U.S. flu vaccines over the current Northern Hemisphere winter from 42% to approximately 50% according to data from the U.S. FDA. Management has previously guided for Seqirus to break even for 2018 but a more severe flu season could see the division deliver its first profit.
29th Jan 2018 - Motley Fool Australia


Seqirus mentions - Seqirus Media Monitoring - 29th Jan 2018

    View this newsletter in full

Burr takes reins to revamp nation's all-hazards preparedness, response law

Brent MacGregor, senior VP of commercial operations at Seqirus, testified at a hearing on updating provisions in the Pandemic and All-Hazards Preparedness Act. He said the firm's partnership with BARDA has allowed Seqirus “to continue to advance the effectiveness of cell-based technology,” an example of a platform technology that the federal government is investing in as a potential for providing a better match — or vaccine antigen-to-circulating virus — “in the event of a mismatch season, as we’re experiencing this year.”
26th Jan 2018 - Ripon Advance


Seqirus mentions - Seqirus Media Monitoring - 26th Jan 2018

    View this newsletter in full

Vaccinating children and teenage can reduce the impact of flu by up to 40%

The flu vaccine does not protect as well as other vaccines because the virus mutates every year. According to Toni Lloret, general manager of Seqirus, the problem is that the WHO recommendations for the components of the vaccine are made six months before flu season begins. "As the virus mutates, the vaccine does not pick up protection against the different strains."
25th Jan 2018 - Cinco Días


Seqirus mentions - Seqirus Media Monitoring - 25th Jan 2018

    View this newsletter in full

PAHPA hearing witnesses question U.S. government’s preparedness, response commitment

Seqirus is part of a public-private partnership with BARDA. Seqirus operates a vaccine production facility in Holly Springs, N.C., a facility characterized as “one of the best examples of a public-private partnership envisioned by the authors of PAHPA when it was originally signed into law,” Brent MacGregor, senior VP of commercial operations at Seqirus, said. Currently, the partners are working on candidate vaccines against the H7N9 strain that’s circulating in China. The ASPR expressed concern about the evolving strain during the HELP Committee’s Jan. 17 hearing. But BARDA’s funding under PAHPA “has been largely episodic funding since 2009,” MacGregor testified, adding emergency supplemental monies provided during pandemics in 2005 and 2009 “have been fully exhausted.”
24th Jan 2018 - Homeland Preparedness News

Health Experts Urge More Funding for Epidemic, Bioterror Response


23rd Jan 2018 - Bloomberg BNA

“Facing 21st Century Public Health Threats: Our Nation’s Preparedness and Response Capabilities, Part 2”

The Statement of Brent MacGregor Senior Vice President, Commercial Operations at Seqirus, on January 23rd, 2018 - testifying to the U.S. Senate Health, Education, Labor and Pensions Committee
23rd Jan 2018 - U.S. Senate

The three most common excuses used by people for not getting vaccinated against influenza

There are three common excuses used by people to avoid getting a flu shot: the flu vaccine doesn't work, it can give you the flu, or the vaccine contains harmful mercury. There are particular vaccines better tailored for the over 65s: Fluzone High Dose and Fluad, and for the over 50s, Flublok Quadrivalent
23rd Jan 2018 - La Opinion


Seqirus mentions - Seqirus Media Monitoring - 24th Jan 2018

    View this newsletter in full

Seqirus boosting output and focusing on just a few vaccines: CSL CEO

During the two-plus years of Seqirus' existence, the new company has worked to both hone its portfolio and boost output of next-gen cell culture flu vaccines, CSL CEO Paul Perreault said. The company is honing its efforts on just a few products such as the Flucelvax cell culture shot and its adjuvanted option called Fluad, Perreault said. So far, the company is alone in producing next-gen cell culture flu vaccines on a commercial scale at a time when efficacy for egg-based flu vaccines has come into question.
23rd Jan 2018 - FiercePharma

Severe flu season has senators evaluating ways to cope with pandemics

Witness and Senior Vice President, Commercial Operations Seqirus, Co-Chair, Alliance for Biosecurity Brent MacGregor said pandemic influenza is one of the most urgent public health threats we face as a nation. "Authorized funding for pandemic influenza has never been included in legislation. As a result, funding for critical BARTA (Biomedical Advanced Research and Development Authority) activities such as vaccine stockpiling, advanced research and development has been largely episodic since 2009," MacGregor said. MacGregor suggested an annual authorization level of at least $535 million to support HHS' influenza pandemic activities.
24th Jan 2018 - WJLA

More Data Needed in Health Emergencies, Lawmakers Told

In the U.S., the federal government needs to help public health agencies better pull together data from various sources during a public health emergency, witnesses said at a Senate committee hearing. They kept returning to the issue of underfunding. Brent MacGregor, senior VP of commercial operations for Seqirus, noted that the "vaccine stockpile as it exists today is a result of underfunding that has occurred particularly since 2009 ... The funding from 2005 to 2009 allowed for building up of a stockpile for various pandemic strains ... but since then the funding has really dropped off." "Our ability to replenish the stockpile, whether with antigen or adjuvant, has been diminished by the lack of sustainable funding. We are in fact working with BARDA [the Biomedical Advanced Research and Development Authority] to develop [a vaccine for] H7N9, but we need sustainable funding going forward to enhance our readiness."
23rd Jan 2018 - Medpage Today


Seqirus mentions - Seqirus Media Monitoring - 23rd Jan 2018

    View this newsletter in full

Flu shots aren't perfect, but scientists are trying to make them better

Scientists dream of creating a universal flu vaccine that could be administered once and prevent sickness for a lifetime. One strategy companies have tried is developing vaccines in other places outside traditional chicken eggs. Seqirus, the vaccine unit of CSL, produced cell-based flu vaccines at commercial scale at one of its facilities last year in what the company called an industry first. Sanofi Pasteur last year acquired Protein Science, which makes Flublok, an influenza vaccine manufactured in insect cells. Now that Sanofi Pasteur has the product, the company will see if it can apply the process more broadly
22nd Jan 2018 - CNBC


Seqirus mentions - Seqirus Media Monitoring - 22nd Jan 2018

    View this newsletter in full

"Only way to prevent NHS being brought to its knees is to give people the right flu jab"

Some time has passed since the UK had a really bad bout of flu and there are predictions that another is on its way. There has been criticism after GPs were asked to use a cheaper flu jab which covers fewer variants of the flu virus. We need better and stronger vaccines and we have them ready for use this year. This vaccine is called Fluad and is available for GPs to order now for the 2018-19 season for people over 65.
21st Jan 2018 - Mirror.co.uk

Flu service recommissioned for 2018-19

In the UK, the national flu vaccination service will run in 2018-19, pharmacy minister Steve Brine has confirmed. The service will include a new adjuvanted trivalent influenza vaccine (aTIV), licensed in 2017. Answering a Parliamentary question, Mr Brine said Public Health England ‘has updated their advice in the Green Book chapter on influenza so that clinicians are aware of the advice of the Joint Committee on Vaccination and Immunisation (JCVI) in relation to the aTIV’.
20th Jan 2018 - The Pharmacist

Pharmacies will be commissioned to provide flu vaccination next winter using trivalent adjuvanted vaccine

In England, community pharmacies will be commissioned to administer flu vaccination to older people (aged over 65 years) and other high-risk groups next winter, and will be expected to provide the trivalent adjuvanted inactivated vaccine for some patients, the Department of Health and Social Care (DHSC) has confirmed.
19th Jan 2018 - Pharmaceutical Journal


Seqirus mentions - Seqirus Media Monitoring - 19th Jan 2018

    View this newsletter in full

Questions and Answers About This Year’s Flu Season

In the U.S., the 2017-2018 flu season is considered “moderately severe.” Large numbers of Americans have fallen ill, and every state except Hawaii has reported widespread flu activity. The flu shot’s efficacy has not yet been calculated because the virus is still spreading, but experts expect it to be about 30 percent. Antivirals are working: of all the samples tested so far by the C.D.C., only 1 percent were resistant to oseltamivir, zanamivir, and peramivir, the ingredients in Tamiflu, Relenza and Rapivab.
18th Jan 2018 - New York Times

Influenza Vaccine in Children: Recommendations From the AAP

In an American Academy of Pediatrics policy statement, annual seasonal influenza vaccination was recommended for all individuals age 6 months or older, including patients with egg allergies. The recommendations emphasized the importance of prompt identification of children suspected of having influenza for initiation of antiviral treatment. Oral oseltamivir, inhaled zanamivir, and intravenous peramivir are all treatment options for influenza in children
18th Jan 2018 - Infectious Disease Advisor

CSL earnings to gain from bad US flu season

According to US Food and Drug Administration data, CSL's vaccine business, Seqirus, has increased its share of US flu vaccines in the 2017-18 season to roughly 50 per cent from 42 per cent last year. The $64 billion blood products giant expects Seqirus to break even this year
18th Jan 2018 - Australian Financial Review

People With HIV Take Note: This Year's Flu Strain Can Be Dangerous, Especially for Elders

This season's flu is considered "moderately severe" and is already "widespread" in 49 states, according to the CDC; the H3N2 strain is considered one of the deadlier, especially for people over 65. Although there's no evidence that that this year's flu is hitting older people with HIV harder than others, there's ample reason for older people with HIV to be cautious. The FDA has approved two flu vaccines specially designed for seniors: Fluzone High-Dose, and FLUAD, which includes an adjuvant that bolsters the body's immune response. Both of these vaccines are recommended for people over the age of 65 living with HIV
17th Jan 2018 - The Body


Seqirus mentions - Seqirus Media Monitoring - 18th Jan 2018

    View this newsletter in full

Think flu season is bad? It could get worse before it’s over

“Flu is everywhere in the U.S. right now,” said Dan Jernigan, director of the influenza division at the national Center for Immunization and Respiratory Diseases. Most flu vaccines are made using eggs, which are less hospitable to growing the H3N2 strain and thus less likely to develop an effective vaccine. That strain goes through more changes over time than other versions, so vaccines are often behind the curve when they reach the general public. Recent advances in manufacturing have yielded two immunizations that aren’t made in eggs: Sanofi’s Flublok and CSL Ltd.’s Flucelvax
17th Jan 2018 - The Denver Post

Rite Aid Corporation Urges People To Get Flu Shot

In the U.S., with the CDC announcing widespread flu activity in 46 states, Rite Aid is urging people to get vaccinated and combat the flu. Rite Aid pharmacies are offering three different types of flu vaccines: the quadrivalent flu vaccine, the standard trivalent vaccine, and a trivalent vaccine with adjuvant, FLUAD.
17th Jan 2018 - Financials Trend


Seqirus mentions - Seqirus Media Monitoring - 17th Jan 2018

    View this newsletter in full

Influenza: Vaccination Department of Health and Social Care written question – answered on 15th January 2018.

Steve Brine The Parliamentary Under-Secretary for Health and Social Care answered a Parliamentary question, in part, by saying: "Public Health England has updated their advice in the Green Book chapter on influenza so that clinicians are aware of the advice of the Joint Committee on Vaccination and Immunisation in relation to the adjuvanted trivalent influenza vaccine. In addition, NHS England wrote to general practitioners and clinical commissioning groups (via NHS England local teams) in December 2017 to provide an update on the use of the adjuvanted trivalent influenza vaccine for 2018/19."
15th Jan 2018 - They Work for You

Think Flu Season Is Bad? It Might Get Even Worse

The influenza virus that’s sickened millions of Americans is already the most widespread outbreak since public health authorities began keeping track more than a dozen years ago. Now, with the threat of more strains emerging, it might get even worse. The flu vaccine being grown in eggs also makes matching to the strains a difficult process. Recent advances in manufacturing have yielded two immunizations that aren’t made in eggs: Sanofi’s Flublok and CSL’s Flucelvax. Flublok is a recombinant vaccine, which includes only the protein expressed on the surface of the influenza virus, while Flucelvax is grown in mammalian cells. Since neither uses eggs in the manufacturing process, it’s possible that the vaccines that result may look more like what’s actually circulating
16th Jan 2018 - Bloomberg

Think flu season is bad? It could get worse before it's over


16th Jan 2018 - Fredericksburg.com

Why the Deadly 2018 Flu Season Could Get Even Worse


16th Jan 2018 - Fortune

Google venture arm backs UK universal flu vaccine company

Vaccitech has raised £20 million from investors including GV, the venture capital arm of Google parent Alphabet. Vaccitech said the cash would help fund its flu vaccine through a two-year clinical trial. The vaccine works by using proteins found in the core of the virus rather than those on its surface. It also stimulates T-cells rather than antibodies — an approach that has yet to convince existing flu vaccine manufacturers like Sanofi, GlaxoSmithKline and CSL’s Seqirus
16th Jan 2018 - The Edge Markets

Google's VC arm, Sequoia China back $27m round in UK's universal flu vaccine maker


16th Jan 2018 - Deal Street Asia

Universal flu vaccine candidate keeps looking promising


16th Jan 2018 - L'Express

Neuraminidase inhibitor indications, recommendations for treating influenza

As 2017 closes out, national influenza activity is increasing in the U.S. All 10 US regions characterized by the CDC have reported elevated outpatient influenza-like illness, i.e., above the national or regional-specific baseline. Of all specimens tested positive for influenza virus by national collaborative laboratories, 81.5% have been confirmed as influenza A; of influenza A specimens tested, the vast majority (approximately 90%) have been subtype H3N2. Of 470 influenza viral specimens tested, 100% remained sensitive to the neuraminidase inhibitors — Tamiflu (oseltamivir, Genentech; and generic), Relenza (zanamivir, GlaxoSmithKline), and Rapivab (peramivir, Seqirus)
16th Jan 2018 - Healio.com


Seqirus mentions - Seqirus Media Monitoring - 16th Jan 2018

    View this newsletter in full

Google venture arm backs UK universal flu vaccine company

Vaccitech has raised £20m from investors including GV, the venture capital arm of Google parent Alphabet, to fund its universal flu vaccine through a two-year clinical trial involving more than 2,000 patients and expand other projects. The vaccine stimulates T-cells rather than antibodies - an approach that has yet to convince existing flu vaccine manufacturers like Sanofi, GlaxoSmithKline and CSL’s Seqirus. Vaccitech CEO Tom Evans is confident the big players will come around if the current mid-stage clinical trial is a success and he will not have a problem in finding a partner to take the product into final-stage Phase III tests
15th Jan 2018 - Reuters

Google invests in UK company developing first ever universal flu vaccine


15th Jan 2018 - The Independent

Google venture arm backs universal flu vaccine clinical trial


15th Jan 2018 - CBC.ca


Seqirus mentions - Seqirus Media Monitoring - 15th Jan 2018

    View this newsletter in full

Three flu deaths reported among Allegheny County residents in past week

In the U.S., three people in Allegheny County have died from flu complications in the past week, the county Health Department confirmed Friday. Health Director Karen Hacker urged residents who are experiencing flu symptoms to contact their health care provider to see if antiviral drugs should be prescribed. The CDC recommends three antiviral drugs: oseltamivir (either generic or with the trade name Tamiflu), zanamivir (trade name Relenza) and peramivir (trade name Rapivab).
12th Jan 2018 - Pittsburgh Post Gazette

San Angelo not spared from widespread flu cases across Texas

This flu season in the U.S., a quadrivalent recombinant influenza vaccine is available (last season, only trivalent recombinant influenza vaccine was available.) For the first time, a cell-grown H3N2 vaccine reference virus was used to produce the H3N2 component of the cell-based vaccine, Flucelvax (the remaining Flucelvax vaccine components were manufactured using egg-grown reference viruses.)
12th Jan 2018 - San Angelo Standard-Times


Seqirus mentions - Seqirus Media Monitoring - 12th Jan 2018

    View this newsletter in full

Rite Aid Urges People to Get Vaccinated Against the Flu as Flu Activity Increases

In the I.S., with the CDC reporting widespread flu activity in 46 states, Rite Aid is urging people to get vaccinated against the flu if they haven’t already done so. Rite Aid pharmacies offer three types of flu vaccines: a quadrivalent flu vaccine, the standard trivalent vaccine, and FLUAD, a trivalent vaccine with adjuvant, an ingredient that helps create a stronger immune response to vaccination, which is approved for people 65 and older.
11th Jan 2018 - Pharmiweb.com

Rite Aid Urges People to Get Vaccinated Against the Flu as Flu Activity Increases


11th Jan 2018 - Business Wire

Here's Where You Can Still Get a 2018 Flu Shot and How Much It Will Cost You

In the U.S., the 2018 flu season is already proving to be a deadly one. People can still get the flu vaccine, often times for free, at retail clinics like CVS, Walgreens, Rite Aid, and Costco. People over the age of 65 are recommended a higher-dose flu shot, such as Fluzone High-Dose and FLUAD.
11th Jan 2018 - Fortune


Seqirus mentions - Seqirus Media Monitoring - 11th Jan 2018

    View this newsletter in full

The flu is here — and so is a new advisory from the CDC

The CDC has issued an advisory on the flu, including the fact that the flu vaccine may not be very effective. Estimates are that it’s about 32% effective, while last year it was 39% effective and most years it’s 40% to 60% effective. Still, vaccination is highly recommended. Antivirals can also shorten the course of the illness
10th Jan 2018 - Harvard Health

The flu vaccine offered 'no significant protection' for elderly people last year

In the UK, the flu vaccination was ineffective in protecting the elderly last winter, health experts have warned. Dr Richard Roberts, head of the Vaccine Preventable Disease Programme in Public Health Wales, said a new vaccine will be introduced in 2018-19 which specifically offers additional protection for the elderly. The jab will contain an adjuvant which helps to boost the immune system
10th Jan 2018 - Wales Online

Is Tamiflu Effective Against This Year's Flu?

For people diagnosed with influenza, doctors may prescribe an antiviral drug. The most common antiviral is probably oseltamivir, better known to consumers under the brand name Tamiflu. Other options include peramivir (Rapivab), and zanamivir (Relenza). While no antiviral is guaranteed to defeat the flu, they typically make the illness less severe, lessening the serious complications that can come with the flu
10th Jan 2018 - Healthline


Seqirus mentions - Seqirus Media Monitoring - 10th Jan 2018

    View this newsletter in full

Update on use of adjuvanted trivalent flu vaccines

We are aware that NHS England circulated a letter to GP practices about the use of adjuvanted trivalent flu vaccine for 2018-19 flu season on 22 December. The letter stated that the advice from the Joint Committee on Vaccination and Immunisation (JCVI) is that the use of the adjuvanted trivalent flu vaccine should be a priority for those aged 75 years and over. The LMC Buying Group launched its vaccine offers for the 2018-19 season in October 2017 and discounts were negotiated with manufacturers of trivalent, quadrivalent and the new adjuvanted trivalent vaccines. In light of NHS England’s letter, Seqirus have extended their early bird discounts until the end of January.
9th Jan 2018 - LMC Buying Group Federation


Seqirus mentions - Seqirus Media Monitoring - 9th Jan 2018

    View this newsletter in full

No, it's not too late to get a flu shot

During the last week of 2017, "influenza activity increased sharply in the United States," according to the CDC. The good news is that it's not too late to reduce your risk by getting a flu shot. Also, if your doctor prescribes an antiviral medication like Tamiflu (oseltamivir), Relenza (zanamivir) and Rapivab (peramivir), be sure to take it. Those are working really well this flu season, the CDC says.
8th Jan 2018 - Medical Express.com

GP practices told to order two different types of flu vaccines amid efficacy fears

In the UK, GP practices have been advised by NHS England to order a separate adjuvanted vaccine, Fluad, to give to over-75s in the 2018/19 flu season. Dr Kieran Sharrock, medical director of Lincolnshire LMC, said that NHS England's advice had come 'too late' for many practices. However, Dr George Kassianos, GP and RCGP immunisation lead, said practices should follow NHS England's advice
5th Jan 2018 - Nursing in Practice


Seqirus mentions - Seqirus Media Monitoring - 8th Jan 2018

    View this newsletter in full

NHS reels as flu epidemic bites: Spike in hospital admissions, GPs overwhelmed, half a million calls to helpline...and worse to come

In the UK, the NHS is bracing itself for a flu epidemic following a surge in cases at hospitals and GP surgeries. The NHS is using a flu jab that does not work for the elderly even though a better one has been available for 20 years. Public Health England has approved the use of the new vaccine – called Fluad – which experts say could save up to 1,700 lives annually. But it won't be available until the autumn, even though it has been offered in Italy, Germany and Luxembourg for almost 20 years.
7th Jan 2018 - Daily Mail

GPs told to order two different types of flu vaccines amid efficacy fears

GP practices have been advised by NHS England to order a separate adjuvanted vaccine, Fluad, to give to over-75s in the 2018/19 flu season. However the directive has been met with concern by some GPs over the potential logistical and financial issues with ordering two separate vaccines. Dr Kieran Sharrock, medical director of Lincolnshire LMC, said that NHS England's advice had come 'too late' for many practices, but Dr George Kassianos, GP and RCGP immunisation lead, said GPs should follow NHS England's advice.
5th Jan 2018 - Pulse

2017 a banner year for North Carolina’s life science ecosystem, from IPOs to startups, deals and more

Seqirus, the world’s second-largest influenza vaccine company, broke ground for a $9 million expansion of its manufacturing facility in Holly Springs. Seqirus said the construction of a 15,000-square-foot warehouse would enable the company to grow its seasonal flu-vaccine business and support its biosecurity partnership with the U.S. government in pandemic preparedness.
5th Jan 2018 - WRAL Techwire

Seqirus and Farmavenix distribute flu vaccine across the country

Seqirus won the contract to supply three types of flu vaccines in thirteen Spanish autonomous regions for the 2017-2018 season. This amounts to four million doses, or 50% of the number of flu vaccines administered in Spain. It has been working with Farmavenix to organise the logistics of the operation
2nd Jan 2018 - Logistica Profesional.com


Seqirus mentions - Seqirus Media Monitoring - 5th Jan 2018

    View this newsletter in full

UK Approved Fluad Flu Vaccine for Seniors 75+

Decades after approval in various countries, the UK National Health Service (NHS) has approved the adjuvanted flu vaccine Fluad. Under this authorization, UK residents 75 years and older will have access to the new flu vaccine. This decision was made because the current flu shot isn't working for the elderly, reports the NHS.
4th Jan 2018 - Precision Vaccinations

Flu activity widespread and increasing in Florida

Flu activity is increasing sharply across the state, averaging above the last two years’ peak levels at this time, according to the latest flu report from the state health department. The flu vaccine is reportedly 10 to 30 percent effective against the H3 strain this year, so federal health officials are recommending early treatment with antiviral drugs, in addition to vaccination. The three antiviral drugs that are approved by the FDA for this flu season are oseltamivir (Tamiflu), zanamivir (Relenza) and peramivir (Rapivab)
4th Jan 2018 - Orlando Sentinel


Seqirus mentions - Seqirus Media Monitoring - 4th Jan 2018

    View this newsletter in full

Flu vaccine efficacy problems prompt switch in UK to Seqirus' Fluad for over-75s

Decades after approvals elsewhere, Seqirus' adjuvanted flu vaccine Fluad is finally set for routine use in the U.K. because the current shot isn't working for the elderly. Following an official finding that the current vaccine didn't work for people 65 and older last year, NHS England is prepping a switch for the next flu season. Under the transition, people 75 and older will get first access to the new vaccine.
3rd Jan 2018 - FiercePharma

Flu consultations with GPs spike

There was a large increase in the number of GP consultations in England for flu-like illness at the end of 2017, and consultations were above expected rates in Wales and Scotland, according to latest figures collated by Public Health England. PHE also confirmed that a new adjuvanted flu vaccine, recently licensed in the UK for use in the elderly, will be recommended for those over 75 in the 2018–2019 vaccination programme. Fluad, marketed by Seqirus, was licensed for use in the UK in late 2017 and is available for use in the 2018–2019 season
3rd Jan 2018 - Pharmaceutical Journal


Seqirus mentions - Seqirus Media Monitoring - 3rd Jan 2018

    View this newsletter in full

Everything every over 65 needs to know about the flu jab: Dr Martin Scurr answers readers' health questions

Studies confirm that in children and young adults, a flu jab helps prevent infection by 70 to 90 per cent, but in the elderly this falls to 40 per cent or lower. The good news is that next flu season, UK GPs are being told to use an injection that’s been available in other European countries for the past 20 years and which is particularly effective against H3N2. Called Fluad, trials have shown it triggers a 61 per cent bigger immune response to this strain in over-65s than other vaccines. It’s also more effective against the other common strain, H1N1.
2nd Jan 2018 - Daily Mail

CDC Alert Warns of Increasing Flu Activity, Advises Health Providers

US influenza activity has significantly increased over recent weeks, and health care providers should be vigilant about diagnosing and treating patients with the virus, according to a CDC Health Advisory issued recently. Three prescription NAI medications are approved by the FDA and recommended for use during the 2017-2018 season: Oral oseltamivir, inhaled zanamivir, and intravenous peramivir.
2nd Jan 2018 - Pharmacy Times

Influenza Vaccine Seems Ineffective Against Current Strain of the Disease


2nd Jan 2018 - Santa Monica Observer


Seqirus mentions - Seqirus Media Monitoring - 2nd Jan 2018

    View this newsletter in full

The flu jab doesn’t work for over-75s, health chiefs admit: NHS bosses order GPs to switch to vaccine used in Europe for 20 years

UK health chiefs have admitted the current flu jab is ineffective for over-75s and ordered doctors to switch to a new version next winter. The new jab, called Fluad, is particularly effective against a strain which is especially dangerous to the elderly called H3N2, also known as Aussie flu. Trials have shown the £9.79 vaccine triggers a 61 per cent bigger immune response to this strain in over-65s than other vaccines
1st Jan 2018 - Daily Mail

Flu jab for over-75s ‘no longer effective’ and will be replaced in the autumn


1st Jan 2018 - Independent

Flu jab boost will benefit the over-75s


1st Jan 2018 - The Times

New NHS flu superjab could help save thousands of elderly from the virus every year


31st Dec 2017 - The Sun

New flu superjab breakthrough to replace vaccine that fails the elderly


31st Dec 2017 - Express.co.uk

Flu activity increasing; not too late to get vaccinated

Concerned with this year’s predominant circulating flu strain, health officials are asking providers to prescribe antiviral medications as soon as possible, particularly to hospitalized and high risk patients. The three antiviral drugs that are approved by the FDA for this flu season are oseltamivir (Tamiflu), zanamivir (Relenza) and peramivir (Rapivab), according to the CDC
29th Jan 2018 - Orlando Sentinel

Got the flu? Easy steps you can take to get better faster


30th Dec 2017 - Fox10TV.com

Business Daily CEO of the Year: CSL’s Paul Perreault takes our top prize

Brian McNamee cast a long shadow. When he clocked off for the last time as CSL chief in 2013, he could boast a list of achievements as remarkable as his tenure had been long. The cliche became a refrain: big shoes to fill. If anyone still harboured reservations as to whether his successor, Paul Perreault, could fill them, this is the year Perrault surely slew those doubts. The group has rapidly grown its global network of centres to collect the blood plasma used by CSL Behring. It will open scores more of the centres this financial year — a rate that the group says is without parallel in the industry
29th Dec 2017 - Herald Sun

AAP Updates Flu Recs to Include New Antiviral (Pediatrics)

The American Academy of Pediatrics issued updates to their 2017-2018 policy statement about influenza prevention and control to reflect the approval of a new antiviral. The AAP updated their online statement to include intravenous peramivir (Rapivab), which was approved by the FDA in September 2017 to treat "acute uncomplicated influenza in non-hospitalized children 2 years and older."
29th Dec 2017 - MedPage Today


Seqirus mentions - Seqirus Media Monitoring - 22nd Dec 2017

    View this newsletter in full

CDC: Influenza Antiviral Medications - Summary for Clinicians

Because of their bad reputation over the past 10 years, the importance of early administration of antivirals to at-risk patients with severe influenza is often overlooked by clinicians. However, during a severe H3N2 flu season, the importance of aggressive treatment is paramount. The CDC posted an extensive review of influenza antiviral medications for both treatment and chemoprophylaxis. Three antivirals are recommended for use in the U.S. during the 2017-2018 flu season: oral oseltamivir (available as a generic version or as Tamiflu), inhaled zanamivir (Relenza), and intravenous peramivir (Rapivab)
21st Dec 2017 - afludiary.blogspot.com

Influenza Antiviral Medications: Summary for Clinicians


20th Dec 2017 - CDC

Saba Button's story is so much more than just a tragic vaccine error

Saba Button was 11 months old when she was vaccinated with a dose of Fluvax (later deemed defective), and became seriously sick. She survived and her family has since received compensation from the State Government (PMH) and CSL (the Melbourne drug manufacturer responsible for the vaccine), and established the Saba Rose Button Foundation in order to provide their daughter with essential therapy
21st Dec 2017 - kidspot.com.au


Seqirus mentions - Seqirus Media Monitoring - 21st Dec 2017

    View this newsletter in full

Flu vaccines, previously problematic for the egg-allergic, are now deemed safe

Health experts are presenting new vaccination guidelines saying there's no safety difference for flu shots given to people with egg allergies and those without. But while the guidelines will likely assuage concerns about allergic reactions, the egg-based production method has come under fire lately for efficacy. Meanwhile, Sanofi and Seqirus offer vaccinations that use alternative manufacturing technologies, and Seqirus this year became the first vaccine maker to produce cell-based flu immunizations on a commercial scale
20th Dec 2017 - FiercePharma

Vaccine to combat seasonal illness - Seqirus advice on how to protect yourself from influenza during the winter months

In Italy, Seqirus released information on the flu and how to protect yourself efficiently. "It may be the case that influenza should not cause great concern in the healthy population, but it can have serious consequences for people in the most at risk groups," according to Prof. Fabrizio Pregliasco, Virologist, Researcher at the Department of Biomedical Sciences for Health at the University of Milan. "In this sense, flu vaccine is, without a doubt, a life-saver for those people in the most fragile categories. These include young children, those over 65 and those suffering from chronic diseases of both respiratory and cardiac nature ".
20th Dec 2017 - Stile.it

2018 Influenza Antiviral Recommendations

Although prevention through vaccination is the best line of defense against flu, treatment options are available and should be administered promptly, especially to high-risk patients. Three prescription antiviral medications are recommended for the treatment of influenza: oral oseltamivir, inhaled zanamivir, and intravenous peramivir
19th Dec 2017 - Medscape.com


Seqirus mentions - Seqirus Media Monitoring - 19th Dec 2017

    View this newsletter in full

What Tennesseans should know about the flu shot

In the U.S., the CDC National Influenza Vaccination Week was observed earlier this month but that doesn’t mean people should stop caring about flu vaccines. The recommendation to not use the nasal spray flu vaccine was renewed for the 2017-2018 season. Only injectable flu shots are recommended. A quadrivalent inactivated flu vaccine, “Afluria Quadrivalent” IIV, was licensed last season after the annual recommendations were published. The age recommendation for “Flulaval Quadrivalent” has been changed from 3 years old and older to 6 months and older to be consistent with FDA-approved labeling
17th Dec 2017 - JacksonSun.com


Seqirus mentions - Seqirus Media Monitoring - 18th Dec 2017

    View this newsletter in full

Expansion just the right medicine

In Australia, two hundred new jobs have been created in Broadmeadows following the expansion of a world-class medical manufacturing plant. CSL opened the $230 million extension to its Broadmeadows plant earlier this month, where it will manufacture albumin. Chief executive Paul Perreault said the new jobs would be created by 2026.
17th Dec 2017 - Star Weekly

Mum's anguish after egg-free flu vaccine is no longer available for autistic son

In the UK, a mum-of-two says she feels “let down” after being told that an egg-free flu vaccine is no longer available for her son who has a severe allergy. Nathan, 18, has been immunised every year until 2016 with Optaflu – which is egg-free. However, the company has stopped making it in Europe. The Southern Derbyshire Clinical Commissioning Group wrote that "the marketing authorisation holders, Seqirus GmbH, have not applied to extend the license and there is no equivalent egg-free vaccine available"
16th Dec 2017 - Derby Telegraph

Many GPs unaware of poor flu vaccine efficacy in 2016/17

Many GPs were unaware of a recent announcement by Public Health England regarding the poor performance of existing flu vaccines in the most recent flu season (2016/17), research by medeConnect has revealed. The survey showed that there was a low awareness amongst GPs regarding the availability of a new adjuvanted flu vaccine, which the JCVI states has been shown to be work better than nonadjuvanted vaccines in the 65+ population, and which is available to order for use in the 2018-19 flu season. This new vaccine, called FLUAD, aims to address the disappointingly low efficacy issues seen with current flu vaccines in these older patients.
15th Dec 2017 - bjfm.co.uk


Seqirus mentions - Seqirus Media Monitoring - 15th Dec 2017

    View this newsletter in full

Should you buy these 3 healthcare shares?

CSL’s shares may be a touch on the expensive side compared to the market average, but I believe that the biotherapeutics company would still be a great buy and hold investment due to its leading immunoglobulin business and its soon to be profitable Seqirus vaccine business. I believe these businesses and the strong underlying demand it is experiencing has put the company in a position to deliver above-average long-term profit growth.
14th Dec 2017 - Motley Fool


Seqirus mentions - Seqirus Media Monitoring - 14th Dec 2017

    View this newsletter in full

Flu vaccinations for people on the margins of society: Sant'Egidio and FIMMG to launch a campaign to give free flu vaccinations to 4,000 people

On December 13, the Community of Sant'Egidio and FIMMG (Italian Federation of General Practitioners) will offer flu shots for the more vulnerable members of society. The event is part of a broader campaign aiming to reach up to 4,000 vulnerable people across 4 Italian cities. The initiative follows last year's pilot experience when flu vaccines were administered to more than 700 people socially on the margins in Rome. This year, Mylan, Pfizer and Seqirus have made free vaccines available
13th Dec 2017 - Sant Egidio

Sant'Egidio and FIMMG to offer free flu shots to vulnerable people


13th Dec 2017 - Farodiroma

Former CEO Brian McNamee to replace John Shine as CSL chair

CSL’s former boss Brian McNamee will return to its board, ready to take over as chairman next year. CSL said that Dr McNamee and Abbas Hussain had been appointed as independent non-executive directors. Mr Hussain’s most recent executive role was global president, pharmaceutical at GlaxoSmithKline, where he managed GSK’s global pharmaceuticals and vaccine business across 150 markets. “I look forward to working closely with Brian and Abbas. Their impressive experience will be additive as we continue to evolve and grow CSL as a fully integrated global biotechnology leader,” Paul Perrault said
13th Dec 2017 - The Australian


Seqirus mentions - Seqirus Media Monitoring - 13th Dec 2017

    View this newsletter in full

Egg-based production faulted as experts predict vaccine might be just 10% effective this season

Based on data from Australia, scientists warn that this season’s flu shot might be only 10% effective. And the reason might lie in the method by which the majority of flu vaccines are made: in eggs. Scientists now stress the importance of a universal flu vaccine and are championing new paths away from the egg-based manufacturing process. Recombinant and cell-based platforms are two other vaccine technologies currently available. Sanofi, through its recent acquisition of Protein Sciences, markets the Flublok family, the only recombinant-based flu shots approved in the U.S. Seqirus’ Flucelvax is also the only FDA-approved cell-based flu vaccine. Seqirus just started manufacturing its cell-based flu vaccines on a commercial scale this season
12th Dec 2017 - FiercePharma

US Influenza Activity Increasing in the United States

Influenza activity is on the rise across the United States, with several influenza activity indicators higher than what is typically seen for this time of year, according to the CDC Morbidity and Mortality Weekly Report. Circulating influenza viruses collected since October 1, 2017 that were tested demonstrated sensitivity to all 3 antiviral medications available for use against influenza including: oseltamivir, zanamivir, and peramivir
12th Dec 2017 - Contemporary Clinic

News of Note—GlaxoSmithKline's Shingrix, Seqirus expansion and more

Among the news of note this week was that Seqirus is investing $9 million to expand its North Carolina flu vaccine manufacturing plant
12th Dec 2017 - FiercePharma


Seqirus mentions - Seqirus Media Monitoring - 12th Dec 2017

    View this newsletter in full

Flu vaccination guidance updated with new evidence on older age groups

In the UK, national vaccination guidance has been updated to reflect evidence suggesting that adjuvanted trivalent influenza vaccines (aTIVs) work better for older patients than other flu jabs. The JCVI has said that the use of this adjuvanted vaccine in those aged 65 years and over “would be both more effective than the non-adjuvanted vaccines currently in use, and also cost-effective.” So far, only one aTIV – called Fluad – has been approved and is available to order for use in the 2018-19 flu season
11th Dec 2017 - Nursing Times


Seqirus mentions - Seqirus Media Monitoring - 11th Dec 2017

    View this newsletter in full

Rite Aid advises consumers get their flu shot in first Facebook live event

Rite Aid hosted its first-ever flu-focused Facebook live event featuring health expert Jennifer Caudle and Rite Aid certified immunizing pharmacist Chris Altman that as of the next day had been viewed more than 3,000 times. The Facebook live event stressed to consumers the importance of getting their flu shots this holiday season. Rite Aid is offering three types of flu vaccines: a quadrivalent flu vaccine which offers protection against four strains of the flu; the standard trivalent vaccine; and FLUAD, a trivalent vaccine with adjuvant, an ingredient that helps create a stronger immune response to vaccination, which is approved for people 65 years old and older
8th Dec 2017 - Drug Store News

Seqirus readies for $9-million expansion project in Holly Springs

CSL's Seqirus unit is planning a $9-million expansion of its manufacturing facility in North Carolina, Triangle Business Journal reported. Seqirus vice president of operations John Anderson said the new 15 000-square-foot warehouse will support the drugmaker's growth in manufacturing activity. Anderson stated that the company is "seeing significant growth in demand" for its Flucelvax quadrivalent vaccine, adding that the increase in manufacturing "will create more jobs over time at the site."
7th Dec 2017 - firstwordpharma.com

New $230m advanced manufacturing plant to create 200 jobs

CSL has opened a new $230 million advanced manufacturing facility at its CSL Behring site in Victoria. The facility is an important addition to the Australian pharmaceutical manufacturing landscape, and is expected to produce therapies with an estimated annual market value of $850 million as well as generate up to 200 new jobs by 2026. “CSL’s investment in Broadmeadows embeds the site into our global plasma manufacturing supply chain, which now supplies lifesaving therapies to patients in more than 60 countries,” said CSL’s CEO, Paul Perreault
7th Dec 2017 - Manufacturers' Monthly


Seqirus mentions - Seqirus Media Monitoring - 8th Dec 2017

    View this newsletter in full

Vaccine giant Seqirus plans $9M expansion, additional jobs at massive Holly Springs plant

Seqirus is investing $9 million in an expansion project at its mammoth production facility in this Wake County town. The company is hosting a ground-breaking ceremony to discuss plans for a new warehouse. Additional jobs also are going to be added at the complex
7th Dec 2017 - WRAL Tech Wire

Flu vaccine company breaks ground on $9M Holly Springs expansion project

Seqirus is expanding its manufacturing facility in Holly Springs to support immediate growth of its seasonal influenza vaccine business and bio-security partnership with the United States government in pandemic preparedness. The company broke ground on a $9 million expansion project that will allow the company to support an increase in manufacturing capacity and support future growth, officials said
7th Dec 2017 - WNCN

Seqirus announces $9M expansion of Holly Springs site

Seqirus announced a $9 million expansion of its Holly Springs site. Executives said the expansion will help Seqirus meet its goal of quadrupling the number of doses of flu vaccine produced on site. "It will probably increase the warehouse staff by about 50 percent," said Dr. John Anderson, Seqirus Vice President of Operations and Holly Springs Site Head. "We will need to have more people to handle more material. Also, we're likely to be operating a late afternoon, late evening shift as well as a day shift."
7th Dec 2017 - abc11.com

Seqirus Breaks Ground for $9M Expansion of Vaccine Plant

Seqirus has broken ground for a $9 million expansion of its massive manufacturing facility in Holly Springs. Seqirus said the construction of a 15,000-square-foot warehouse would enable the company to grow its seasonal influenza vaccine business and support its biosecurity partnership with the U.S. government in pandemic preparedness.
7th Dec 2017 - NC Biotech

CSL opens new $230m Melbourne plant

In Australia, CSL has expanded its local manufacturing capacity with the opening of a $230 million facility, which will add 200 new jobs and generate $850m worth of product each year. The company today officially opened its new advanced manufacturing facility at its CSL Behring site at Broadmeadows, Victoria. “CSL’s investment in Broadmeadows embeds the site into our global plasma manufacturing supply chain, which now supplies lifesaving therapies to patients in more than 60 countries,” CSL’s chief executive, Paul Perreault, said
7th Dec 2017 - The Australian

Seqirus Announces Be FLUent Collaborative

Seqirus, in partnership with health care provider advocacy organizations, announced the launch of Be FLUent, a collaborative initiative that brings together nurse practitioners, physician assistants and pharmacists to drive dialogue about influenza prevention between health care providers and their patients age 65 and older. "We're proud to be partnering with the American Pharmacists Association, the American Nurse Practitioner Foundation and the Physician Assistant Foundation to elevate the importance of flu prevention in older adults," said Gregg C. Sylvester, MD, MPH, Global Head, Medical Affairs, Seqirus
7th Dec 2017 - Home Care

Healthcare Provider Groups Collaborate to Protect Seniors Against Flu


7th Dec 2017 - Associations Now

What’s New this Flu Season?

This season, the CDC advises that only injectable flu vaccines are recommended. Some flu shots protect against three flu viruses and some protect against four flu viruses. A quadrivalent inactivated flu vaccine, “Afluria Quadrivalent” IIV, was licensed last season after the annual recommendations were published. The age recommendation for “Flulaval Quadrivalent” has been changed from 3 years old and older to 6 months and older to be consistent with FDA-approved labeling. The trivalent formulation of Afluria is recommended for people 5 years and older (from 9 years and older) in order to match the Food and Drug Administration package insert
7th Dec 2017 - Sun News Report


Seqirus mentions - Seqirus Media Monitoring - 7th Dec 2017

    View this newsletter in full

UK trumpets life sciences post-Brexit ‘sector deal’

The UK government has secured commitments from 25 international organisations that it says will ensure the country remains a pharma hub after it leaves the EU. MSD, GSK and AstraZeneca projects were highlighted, as well as a $100m contract from The Medicines Company to test a cholesterol-lowering drug at the University of Oxford’s clinical trials unit, a £40m investment from Seqirus to build a fill-and-finish vaccine plant in Liverpool and an initiative between Janssen and the University of Oxford to find novel clinical trial approaches for mental health disorders
6th Dec 2017 - PMLive.com

Seqirus readies for $9M expansion project in Holly Springs

Two years after CSL acquired Novartis' global influenza vaccine business for $275 million, Seqirus continues to ramp up production at its Holly Springs site. And now the company is preparing for a $9 million facility expansion for a new, 15,000-square-foot warehouse to support the company’s growth in manufacturing activity, says Seqirus VP of Operations and Holly Springs Site Head Dr. John Anderson. Seqirus will hold a groundbreaking for the new warehouse Thursday, with expected completion in just under a year, he says
6th Dec 2017 - Biz Journals.com


Seqirus mentions - Seqirus Media Monitoring - 6th Dec 2017

    View this newsletter in full

JCVI committee recommends using the adjuvanted vaccine for seasonal influenza

The Joint Committee on Vaccination and Immunization (Joint Committee on Vaccination and Immunization, JCVI ), has preferentially recommended the adjuvanted vaccine for the prevention of seasonal influenza in people over 65 years during the next flu campaign. The committee advises Primary Care physicians and other health professionals to strongly look at adjuvanted Seqirus vaccine as the most effective tool with the best cost / efficacy profile compared to conventional vaccines.
5th Dec 2017 - Consalud.es

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors

Seqirus today, in partnership with leading health care provider advocacy organizations, announced the launch of Be FLUent, a collaborative initiative that brings together nurse practitioners (NPs), physician assistants (PAs) and pharmacists to drive dialogue about influenza (flu) prevention between health care providers and their patients age 65 and older.
4th Dec 2017 - USA LifeSciences.com

Australia: Paragon to acquire Seqirus’ blood business

Paragon Care has agreed to acquire the immunohaematology business unit from CSL subsidiary Seqirus for A$8.5 million (US$6.4 million).
4th Dec 2017 - Health Investor Asia

Rite Aid Teams Up with Dr. Jennifer Caudle to Remind People to Get Vaccinated During National Influenza Vaccination Week

In an effort to encourage people to get a flu shot, Rite Aid is teaming up with Dr. Jennifer Caudle during National Influenza Vaccination Week. This year Rite Aid is offering three types of flu vaccines: a quadrivalent flu vaccine, which offers protection against four strains of the flu, the standard trivalent vaccine, and FLUAD, a trivalent vaccine with adjuvant, an ingredient that helps create a stronger immune response to vaccination, which is approved for people 65 and older
5th Dec 2017 - ADVFN.com

Rite Aid Teams Up with Dr. Jennifer Caudle to Remind People to Get Vaccinated During National Influenza Vaccination Week


5th Dec 2017 - Pharmiweb.com

Health expert Jennifer Caudle joins Rite Aid in promoting flu shot availability


5th Dec 2017 - Drug Store News


Seqirus mentions - Seqirus Media Monitoring - 5th Dec 2017

    View this newsletter in full

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors

Seqirus, in partnership with leading health care provider advocacy organizations, announced the launch of Be FLUent, a collaborative initiative that brings together nurse practitioners, physician assistants and pharmacists to drive dialogue about influenza prevention between health care providers and their patients age 65 and older. "We're proud to be partnering with the American Pharmacists Association, the American Nurse Practitioner Foundation and the Physician Assistant Foundation to elevate the importance of flu prevention in older adults," said Gregg C. Sylvester, MD, MPH, Global Head, Medical Affairs, Seqirus
4th Dec 2017 - kswo.com

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors


4th Dec 2017 - menafn.com

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors


4th Dec 2017 - PR Newswire

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors


4th Dec 2017 - gurufocus.com

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors


4th Dec 2017 - Yahoo Finance

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors


4th Dec 2017 - rfdtv.com

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors


4th Dec 2017 - Finance attitude.com

FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors


4th Dec 2017 - wnky.com

Confirmed cases of influenza in Alberta triples last season

There have been 1,147 laboratory-confirmed cases of flu this season in Alberta, compared to just 374 last year at this stage. People are advised to get vaccinated. Only one type of influenza vaccine is being offered free of charge: Fluzone. The influenza vaccine FLUAD, designed to boost the immune response in seniors, will not be available except to seniors living in long-term care or supportive living
4th Dec 2017 - Medicine Hat News


Seqirus mentions - Seqirus Media Monitoring - 4th Dec 2017

    View this newsletter in full

New Smithsonian Exhibition Explores Pandemics and Emerging Infectious Diseases

The Smithsonian's National Museum of Natural History will mark the 100th anniversary of the Spanish Flu Pandemic with a new exhibition, `Outbreak: Epidemics in a Connected World,` which will open May 18 and remain for three years.The National Museum of Natural History acknowledges the support of Rockefeller Foundation, Lyda Hill Foundation, Johnson & Johnson Innovation, Open Philanthropy, Skoll Global Threats Fund, Page Family Foundation Donor Advised Fund, Seqirus, Anders Foundation, National Foundation for Infectious Diseases, Centers for Disease Control and Prevention, Infectious Diseases Society of America and RTI International
2nd Dec 2017 - Infection Control Today

BRIEF-Paragon Care Ltd Agreed To Acquire Immunohaematology Business Unit

Paragon Care has agreed to purchase the Immunohaematology Business Unit of Seqirus for a total consideration of $8.5m
1st Dec 2017 - Reuters


Seqirus mentions - Seqirus Media Monitoring - 1st Dec 2017

    View this newsletter in full

FDA Approves Four-Strain Flu Vaccine for Children

The U.S. FDA recently expanded the age indication for Seqirus’ Afluria Quadrivalent influenza vaccine to include patients aged five years or older. Approval was based on a randomized trial including 2,278 children aged five to 17 years in which Afluria Quadrivalent demonstrated non-inferiority to a comparator vaccine containing the same virus strain targets
30th Nov 2017 - The Vaccine Reaction.org

Why Your Excuses for Not Getting a Flu Shot Stink

Teens and adults should consider a quadrivalent vaccine, which protects against four flu strains. People 50 and older have the option of Flublok Quadrivalent, which has triple the dose of other quadrivalents. Those 65 and older have two more choices: Fluzone High-Dose and Fluad. Both protect against only three strains, but Fluzone has four times the dose and Fluad adds an ingredient to boost the immune system’s response
30th Nov 2017 - Consumer Reports.org

New Smithsonian Exhibition Explores Pandemics and Emerging Infectious Diseases

The Smithsonian’s National Museum of Natural History will mark the 100th anniversary of the Spanish Flu Pandemic with a new exhibition, “Outbreak: Epidemics in a Connected World,” which will open May 18 and remain for three years.The National Museum of Natural History acknowledges the support of Rockefeller Foundation, Lyda Hill Foundation, Johnson & Johnson Innovation, Open Philanthropy, Skoll Global Threats Fund, Page Family Foundation Donor Advised Fund, Seqirus, Anders Foundation, National Foundation for Infectious Diseases, Centers for Disease Control and Prevention, Infectious Diseases Society of America and RTI International
30th Nov 2017 - Smithsonian mag.com


Seqirus mentions - Seqirus Media Monitoring - 30th Nov 2017

    View this newsletter in full

Flu Shots for Seniors

There are two different flu shots – Fluzone High Dose and FLUAD – that are designed specifically for people age 65 and older. Approved for U.S. use in 2009, Fluzone High-Dose is a high-potency vaccine that contains four times the amount of antigen as a regular flu shot does; available in the U.S. since last year, FLUAD contains adjuvant MF59 that helps create a stronger immune response. In a 2012 Canadian observational study, FLUAD was 63% more effective than a regular flu shot
29th Nov 2017 - Queens Gazette

What’s new this flu season? CDC provides insight

The CDC said there are a few new things this flu season, including a quadrivalent inactivated flu vaccine, “Afluria Quadrivalent” IIV, which was licensed last season after the annual recommendations were published. The trivalent formulation of Afluria is recommended for people 5 years and older (from 9 years and older)
28th Nov 2017 - Williams News.com


Seqirus mentions - Seqirus Media Monitoring - 27th Nov 2017

    View this newsletter in full

Four deaths in Alberta to influenza so far

In Alberta, Canada, only one type of influenza vaccine is being offered free of charge: Fluzone as an injection. FLUAD, designed to boost the immune response in seniors, will not be available except to seniors living in long-term care or supportive living. Some pharmacists may choose to offer FluMist and/or FLUAD to Albertans for a fee paid by the patient
25th Nov 2017 - Medicine Hat News

NHS dishing out super-charged flu vaccine "could save hundreds of lives every year"

A super-charged flu vaccine must be brought in to save hundreds of lives, the NHS has been told. The jab is cost-effective and there are no concerns about its safety, the Joint Committee on Vaccination and Immunisation said. This is particularly relevant for older people who typically have weaker immune systems and do not respond as well to conventional vaccines
24th Nov 2017 - The Sun


Seqirus mentions - Seqirus Media Monitoring - 24th Nov 2017

    View this newsletter in full

Government advisors back the adoption of new type of flu vaccine for older patients

Giving a new influenza vaccine to people aged 65 and over would be “more effective”, according to a committee of experts, which has called on health bodies in England to consider a change in policy. The JCVI has asked bodies in charge of immunisation policy to consider switching to the new jab, starting with the over 75s. So far, just one aTIV – called Fluad – has been approved for use in the UK and, therefore, currently available to GPs and other healthcare professionals to order for the 2018-19 flu season
23rd Nov 2017 - Nursing Times


Seqirus mentions - Seqirus Media Monitoring - 23rd Nov 2017

    View this newsletter in full

JCVI advocates adjuvanted influenza vaccine for patients aged 65 years and over for this flu season

The Joint Committee on Vaccination and Immunisation has advised that GPs and other healthcare professionals in England should consider using Seqirus’ adjuvanted seasonal influenza vaccine, FLUAD, for the 2018-19 flu season. FLUAD shows an increased breadth of antibody response when compared with non-adjuvanted influenza vaccines, resulting in potentially increased cross protection against drifted influenza strains in older adults
22nd Nov 2017 - GMJournal.co.uk

JCVI recommends FLUAD for over 65s during 2018-19 flu season

The Joint Committee on Vaccination and Immunisation has advised that healthcare professionals in England should consider using FLUAD for the 2018-19 flu season, as it is both more effective in preventing influenza, and more cost-effective in the 65 years and over age group, when compared to conventional non-adjuvanted vaccines. Dr George Kassianos, GP and immunisation expert, said that "use of this adjuvanted vaccine is expected to result in fewer infections, fewer GP consultations and hospital admissions, and a significantly reduced winter burden on the NHS"
17th Nov 2017 - BJFM

10 Ways to Prevent Cold and Flu This Winter

“Because immune defenses decline with age, seniors should receive either a high dose vaccine or a vaccine with an adjuvant than enhance the immune response such as Fluad” says Dr. Pat Salber, editor-in-chief of The Doctor Weighs In Website. The CDC recommends that everyone over the age of 6 month receive the flu shot every year
22nd Nov 2017 - Newsmax.com


Seqirus mentions - Seqirus Media Monitoring - 21st Nov 2017

    View this newsletter in full

'Use adjuvanted flu vaccine in over-65s next winter', JCVI recommends

GPs should consider using an adjuvanted flu vaccine for the 2018/19 flu season as they are more effective than currently available vaccines, the Joint Committee for Vaccinations and Immunisations (JCVI) has recommended. The JCVI acknowledged in its November meeting that the adjuvanted vaccine Fluad is both more cost effective and more clinically effective than the currently available flu vaccine for over-65s
20th Nov 2017 - Pulse

Why now is a good time for a flu shot

There are two flu vaccines intended for people who are sixty-five years and older. The “high dose” vaccine has four times as much antigen as the regular flu shot and has been found to be 24% more effective in preventing flu infections. Another option is the “adjuvanted” flu vaccine, Fluad. This vaccine is designed to create a stronger immune response to vaccination, and one study showed that Fluad was 63% more effective than standard dose, unadjuvanted flu shot
20th Nov 2017 - Courier Herald


Seqirus mentions - Seqirus Media Monitoring - 20th Nov 2017

    View this newsletter in full

What’s new this flu season? CDC provides insight

According to the CDC, getting an annual flu vaccine is the first and best way to protect yourself and your family from the flu. A quadrivalent recombinant flu vaccine (“Flublok Quadrivalent” RIV) is newly available this season. A quadrivalent inactivated flu vaccine, “Afluria Quadrivalent” IIV, was licensed last season after the annual recommendations were published
17th Nov 2017 - Verde Independent

Government advisers back adjuvanted flu vaccine for over 65s from 2018

The Joint Committee for Vaccinations and Immunisations (JCVI) has said the adjuvanted flu vaccine ‘would be more effective than the non-adjuvanted vaccines currently in use’ in those aged over 65 , according to minutes from its latest meeting. It added that cost modelling shows the vaccine would be ‘highly cost-effective’ in both the 65-74 and over 75 age groups.
17th Nov 2017 - GP Online

Use new flu vaccine in over 65s for 2018/19 flu season, says JCVI

The Joint Committee on Vaccination and Immunisation (JCVI) have recommended that a different, adjuvanted flu vaccine is used in over 65s for the 2018/19 flu season. As there is an adjuvanted vaccine available for practices to order for the 2018/19 flu season, the JCVI has asked Public Health England, the Department of Health and NHS England to ‘give consideration to the evidence that had been provided on the provision of the adjuvanted flu vaccine to those over 65’
17th Nov 2017 - Nursing in Practice


Seqirus mentions - Seqirus Media Monitoring - 17th Nov 2017

    View this newsletter in full

BioCryst To Present At 29th Annual Piper Jaffray Healthcare Conference

BioCryst executives are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the 29th Annual Piper Jaffray Healthcare Conference in New York on November 28.
16th Nov 2017 - The Street

BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference


16th Nov 2017 - yahoo.com


Seqirus mentions - Seqirus Media Monitoring - 15th Nov 2017

    View this newsletter in full

CDC Updates Guidelines for Seasonal Influenza Vaccines

Updated recommendations from the Advisory Committee on Immunization Practices for influenza vaccinations in 2017 and 2018 were recently published in the US Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report. Two new licensures are supplied in the update, Flublok Quadrivalent and Afluria Quadrivalent for use in persons ≥18 years of age
14th Nov 2017 - Infectious Disease Advisor


Seqirus mentions - Seqirus Media Monitoring - 14th Nov 2017

    View this newsletter in full

£40m investment to create 100 new jobs to Liverpool

Nearly 100 high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of a £40m investment. In addition to its role in the supply of seasonal influenza vaccine, Seqirus is a global leader in pandemic response. The company is contracted by the UK Government to be in constant a state of readiness for the production of pandemic influenza vaccine during a pandemic emergency
13th Nov 2017 - Click Liverpool

Major UK investment to boost influenza vaccine production, jobs and exports

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment. Gordon Naylor, President of Seqirus, said: “Our Liverpool site, the largest influenza vaccine manufacturing facility in the UK, and one of the largest in Europe, is well-placed to supply the UK with an enhanced influenza vaccine for people aged 65 years plus. It will also be an export success story, primed to supply this vaccine to countries where it is already licensed in Europe and North America, and to countries in Latin America and Australasia where regulatory submissions are ongoing"
13th Nov 2017 - pressat.co.uk

CSL: Major UK investment to boost influenza vaccine production, jobs and exports

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment. Dr Laura O'Brien, Vice President of Operations and Site Head at Liverpool, said: "Speed is of the essence in a pandemic situation. This investment means we can complete production of more pandemic vaccine much more rapidly, saving vital days in getting vaccines out to protect the British population as well as to other countries in the region."
13th Nov 2017 - 4 Traders

Jobs created as flu vaccine firm makes major investment

Nearly 100 high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of a £40m investment. In addition to its role in the supply of seasonal influenza vaccine, Seqirus is a global leader in pandemic response. The company is contracted by the UK Government to be in constant a state of readiness for the production of pandemic influenza vaccine during a pandemic emergency
13th Nov 2017 - The Business Desk


Seqirus mentions - Seqirus Media Monitoring - 13th Nov 2017

    View this newsletter in full

Nearly 100 jobs to be created in Liverpool

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment. Gordon Naylor, President of Seqirus, said: "Our Liverpool site, the largest influenza vaccine manufacturing facility in the UK, and one of the largest in Europe, is well-placed to supply the UK with an enhanced influenza vaccine for people aged 65 years plus. It will also be an export success story, primed to supply this vaccine to countries where it is already licensed in Europe and North America, and to countries in Latin America and Australasia where regulatory submissions are ongoing"
10th Nov 2017 - Gears Of Biz

Liverpool flu firm creates 100 hi-tech jobs

Liverpool is to benefit to the tune of 100 new high-tech jobs and it’s all connected to combatting flu. The BBC reports the new roles are being created due to flu vaccination firm Seqirus’ £40m project, which will allow new vaccines to be created more quickly at its plant in Speke. The plant provides around half of the flu vaccine used in the UK
10th Nov 2017 - Recruiter

Emails show Battle Creek VA worries about some flu shots

An email written on October 16 and obtained by the Newschannel 3 I-Team shows internal worries over a flu vaccine administered by the Battle Creek VA due to particulates being found in the serum. The manufacturer of the vaccine, Seqirus, according to the email, was contacted immediately to inspect the batch of vaccines affected. The company later determined the vaccines that may have been administered with the particulates were safe
11th Nov 2017 - wwmt.com

Docs push flu shots for adults 65 and older

With some indications that this year’s flu season could hit older adults particularly hard, doctors are encouraging people to not only get their flu vaccinations, but pay careful attention to which vaccination they get. There are two shots available in the U.S. specifically for people over 65: Fluzone contains four times the amount of antigen contained in traditional flu shots; Fluad contains an adjuvant that enhances immune response
9th Nov 2017 - The Bulletin


Seqirus mentions - Seqirus Media Monitoring - 10th Nov 2017

    View this newsletter in full

Flu vaccine factory in Liverpool creates 100 new jobs

Seqirus is creating 100 new high-tech jobs by expanding its operation in Liverpool. Dr Laura O'Brien, vice president of operations and site head at Liverpool, said: "This investment means we can complete production of more pandemic vaccine much more rapidly, saving vital days in getting vaccines out to protect the British population as well as to other countries around the world." Liverpool Metro Mayor Steve Rotheram said the development "fits in nicely to the burgeoning life sciences cluster" in the city"
9th Nov 2017 - BBC

£40m Seqirus flu jab investment creates almost 100 new jobs for Liverpool

Almost 100 new jobs have been announced for Liverpool by a world renowned flu vaccine company: the cutting edge, hi-tech roles have been created via a £40m investment by Seqirus. Mayor Anderson said; “This £40m investment by Seqirus is fantastic news for Liverpool"
9th Nov 2017 - Liverpool Echo

Seqirus investing $52M, adding 100 jobs to U.K. flu vaccine site prompted by thoughts of pandemics

Seqirus not only makes seasonal vaccines to help protect consumers against the flu, it also is contracted by the UK government to be in constant a state of readiness in case of a pandemic. That has prompted the world's second-largest flu vaccine maker to invest another £40 million to its site in Liverpool and add about 100 jobs so it can shorten the time it takes to respond to an outbreak
9th Nov 2017 - FiercePharma

Seqirus invest £40m & create new jobs

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus, as a result of major new £40m investment. Gordon Naylor, President of Seqirus said: “Our Liverpool site, the largest influenza vaccine manufacturing facility in the UK, and one of the largest in Europe, is well-placed to supply the UK with an enhanced influenza vaccine for people aged 65 years plus"
9th Nov 2017 - Zenoot.com

Seqirus announces £40m UK fill-and-finish flu vaccine facility

Seqirus has announced a £40 million investment into a new fill-and-finish facility at its manufacturing site in Liverpool, UK – a move which the company says will create 88 new high-tech jobs, bringing total staff levels at the site to more than 700
9th Nov 2017 - Pharmafile.com

Seqirus investing $52M, adding 100 jobs to U.K. flu vaccine site prompted by thoughts of pandemics

Seqirus, the world's second largest flu vaccine maker, is adding a fill-finish operation to its site in Liverpool, U.K. Seqirus not only makes seasonal vaccines to help protect consumers against the flu, it also is contracted by the UK government to be in a constant state of readiness in case of a pandemic. That has prompted the world's second-largest flu vaccine maker to invest another £40 million to its site in Liverpool and add about 100 jobs so it can shorten the time it takes to respond to an outbreak.
9th Nov 2017 - ichainnel.com

Major UK investment to boost influenza vaccine production, jobs and exports

The new fill-and-finish facility will support the growing demand for Seqirus’ adjuvanted influenza vaccine designed for people aged 65+, and strengthen the reliability of flu vaccine supply and bolster any future capacity for a proactive pandemic response. This investment will drive economic growth by boosting the Seqirus workforce in Liverpool to over 700 highly skilled workers. This will assist in supporting supplier partnerships and in increasing exports.
9th Nov 2017 - First Word Pharma.com

Will This Year's Flu Shot Be Effective?

Last year's flu shot was only 20 percent to 30 percent effective because it was grown in eggs, according to the authors of a new report. The egg process is not unusual, but a mutation in the predominant flu virus H3N2 limited the vaccine's potency, said study co-author Dr. John Treanor. Two new methods of producing vaccines are being tried: both -- cell culture (Flucelvax) and DNA (Flublok) -- are licensed by the U.S. FDA
9th Nov 2017 - newsmax.com

Will This Year's Flu Shot Be as Weak as Last Season's?


9th Nov 2017 - Medline Plus.gov

To Your Good Health: A primer on the 2017 flu season vaccines

Adults over 65 may benefit more from the high-dose trivalent flu vaccine (Fluzone High-Dose) or from Fluad, which contains an adjuvant. Adults age 18-64 with fear of needles might consider the intradermal low-dose quadrivalent vaccine (Fluzone intradermal). Another option for people with needle phobia is the standard trivalent vaccine (Afluria) using a jet injector device
8th Nov 2017 - Roanoke.com


Seqirus mentions - Seqirus Media Monitoring - 9th Nov 2017

    View this newsletter in full

Nearly 100 jobs to be created in Liverpool

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment announced today. Gordon Naylor, President of Seqirus, said: Our Liverpool site, the largest influenza vaccine manufacturing facility in the UK, and one of the largest in Europe, is well-placed to supply the UK with an enhanced influenza vaccine for people aged 65 years plus. It will also be an export success story, primed to supply this vaccine to countries where it is already licensed in Europe and North America, and to countries in Latin America and Australasia where regulatory submissions are ongoing”
8th Nov 2017 - ITV

Seqirus to invest £40 million into UK vaccine manufacturing site


8th Nov 2017 - The Pharma Letter

Influenza specialist's investment to create almost 100 jobs


8th Nov 2017 - Insider Media

Major UK investment to boost influenza vaccine production, jobs and exports


8th Nov 2017 - Liverpool City Region Local Enterprise Partnership

Seqirus's Gordon Naylor is interviewed about the company's multi-million pound investment in jobs at its local flu vaccine manufacturing facility on the BBC Radio Merseyside Tony Snell in the Morning Show

Peter Salt, standing in for Tony Snell in the Morning interviews Seqirus's Gordon Naylor (7m 50 sec- 8m 25sec into the show) and he asks Gordon Naylor about the £40m investment in the local flu vaccine manufacturing site which will create just under 100 jobs for the city.
8th Nov 2017 - BBC Radio Merseyside

100 new high tech jobs created at the Liverpool manufacturing site of Seqirus (news feature begins 6m 50sec into programme and runs to 9m 15sec)

BBC North West Tonight reports on Seqirus' multi-million pound new fill-and-finish facility. With the visit of the UK Minister Greg Clark MP to open the factory the programme looks at how this facility will support the growing demand for Seqirus’ adjuvanted influenza vaccine designed for people aged 65+, (among other matters), and how this investment strengthens the reliability of flu vaccine
8th Nov 2017 - BBC Northwest Tonight

Will This Year's Flu Shot Be as Weak as Last Season's?

Lots of people came down with influenza last year despite getting a flu shot -- and researchers can't promise this season's vaccine will be any more effective. Last year's shot was only 20 percent to 30 percent effective because it was grown in eggs, according to the authors of a new report. Two new methods of producing vaccines are being tried: both these methods -- cell culture (Flucelvax) and DNA (Flublok) -- are licensed by the U.S. FDA
8th Nov 2017 - U.S. News

Study: H3N2 mutation in egg-based vaccines lowered efficacy


8th Nov 2017 - CIDRAP

CDC: Too early to tell if flu shot will be more effective than last year


8th Nov 2017 - UPI.com

Your Good Health: Any approved vaccine can protect you from flu

Adults over 65 may benefit more from the high-dose trivalent vaccine (Fluzone High-Dose) or from Fluad, which contains an adjuvant. Adults age 18-64 with fear of needles might consider the intradermal low-dose quadrivalent vaccine (Fluzone intradermal). This uses a tiny (1.5-mm), ultra-thin needle. Another option for people with needle phobia is the standard trivalent vaccine (Afluria) using a jet injector device
8th Nov 2017 - Times Colonist


Seqirus mentions - Seqirus Media Monitoring - 8th Nov 2017

    View this newsletter in full

Industry's favored flu shot production process hurt efficacy last year: study

Vaccine producers have made flu shots with eggs for decades, but a new study says the manufacturing process curbed the efficacy of last year's shot and warns that the problem could repeat this year. A vast majority of flu vaccines are still made with eggs by the market's top players—Sanofi, Seqirus and GlaxoSmithKline—but industry has been working to advance cell-based options. Seqirus over the summer touted its industry-leading capacity for large-scale production of cell-based shots
7th Nov 2017 - FiercePharma

How the incredible, edible egg may actually be hampering your flu vaccine

The U.S. government office charged with preparing the country to deal with flu pandemics has recognized the limitations of egg-based flu vaccine production for a while. For more than a decade BARDA has been working with manufacturers to encourage them to move some portion of production out of eggs. Its funding helped foster development of the two flu vaccines on the market that aren’t made in eggs — FluBlok, a recombinant vaccine developed by Protein Sciences (recently acquired by Sanofi Pasteur) and Flucelvax, produced in the U.S. by Seqirus
7th Nov 2017 - Stat News

Outdated technology makes flu vaccine only 20 percent effective

Last year's flu vaccine should have matched the circulating virus strains that made people sick, but it was only 43 percent effective. This year's flu vaccine will be only 20 percent effective, and it's due to chicken eggs. There are currently two non-chicken egg flu vaccines made in the U.S. One is FLUCELVAX, and is grown in canine kidney cells, and the second, Flublok, is grown in insect cells
7th Nov 2017 - Digital Journal

Seniors have a few flu shot options

There are two different flu shots — Fluzone High Dose and FLUAD — that are designed specifically for people age 65 and older. Available in the U.S. since last year, FLUAD contains an added ingredient called adjuvant MF59 that also helps create a stronger immune response. In a 2012 Canadian observational study, FLUAD was 63 percent more effective than a regular flu shot
7th Nov 2017 - NewsOK.com

Doc: Primer on the 2017 flu season vaccines

Adults over 65 may benefit more from the high-dose trivalent vaccine (Fluzone High-Dose) or from Fluad, which contains an adjuvant. Adults age 18-64 with fear of needles might consider the intradermal low-dose quadrivalent vaccine (Fluzone intradermal). This uses a tiny (1.5-mm), ultra-thin needle. Another option for people with needle phobia is the standard trivalent vaccine (Afluria) using a jet injector device
7th Nov 2017 - Detroit News

BioCryst Reports Third Quarter 2017 Financial Results

BioCryst announced today its financial results. For the nine months ended September 30, 2017, revenues increased to $21.3 million from $17.4 million in the first nine months of 2016. The increase in revenue was primarily due to $7.0 million of milestone payments associated with the Canadian regulatory and FDA sNDA approvals of RAPIVAB, and to a lesser extent a $1.2 million increase in royalty revenue from Shionogi, Green Cross Corporation and Seqirus
7th Nov 2017 - TMC Net

BioCryst Reports Third Quarter 2017 Financial Results


7th Nov 2017 - Globe Newswire.com

BioCryst Reports Third Quarter 2017 Financial Results


7th Nov 2017 - Seeking Alpha


Seqirus mentions - Seqirus Media Monitoring - 7th Nov 2017

    View this newsletter in full

Flu Vaccine “Factories” Create Errors That Reduce Protection

The flu vaccine used during the 2016–17 flu season was only 43 percent effective against the predominant influenza A H3N2 strain, and the lack of protection has been almost as low in other years. Two studies now suggest a new reason for the problem: The vaccine strain mutates during the manufacturing process in ways that cause mismatches with real circulating flu strains. Two U.S. influenza vaccines do not use egg-adapted strains: FLUCELVAX is grown in canine kidney cells, and Flublok is grown in insect cells
6th Nov 2017 - Scientific American

Here’s One Reason Flu Vaccines Are So Lousy: They’re Grown in Eggs


6th Nov 2017 - NBC News


Seqirus mentions - Seqirus Media Monitoring - 6th Nov 2017

    View this newsletter in full

Start of the seasonal anti-flu campaign

Health authorities in Italy have already issued 100,000 vaccines to more than 600 family medical doctors. There are three types this year - Fluarix Tetra, Intanza and Fluad. Doctors will decide on the suitability of the vaccine for each person
5th Nov 2017 - Gazzetta del Sud


Seqirus mentions - Seqirus Media Monitoring - 3rd Nov 2017

    View this newsletter in full

Turbo influenza vaccine to be rolled out in Australia after deaths in horror season

Australian Health Minister Greg Hunt said in-principle agreements had been reached with two companies to provide stronger flu shots that would target older people; Seqirus will produce FLUAD, which contains an adjuvant, and Sanofi Pasteur will produce Fluzone High Dose, which contains four times the antigen of a standard seasonal influenza vaccine
2nd Nov 2017 - News.com.au

Turbo influenza vaccine to be rolled out in Australia after deaths in horror season


2nd Nov 2017 - Herald Sun

Turbo influenza vaccine to be rolled out in Australia after deaths in horror season


2nd Nov 2017 - Courier Mail


Seqirus mentions - Seqirus Media Monitoring - 2nd Nov 2017

    View this newsletter in full

Study Explains Low Effectiveness of Flu Shots

The low effectiveness of the seasonal flu vaccine is likely caused by problems with the way the virus is grown in chicken eggs, according to a study by scientists at The Scripps Research Institute. There are two flu vaccines that aren’t grown in eggs: Flucelvax, a cell-based flu shot made in dog kidney cells that were taken from a Cocker Spaniel in 1958 and grown in a lab ever since, and Flublok, which is grown in the cells of an insect
1st Nov 2017 - Daily Hornet


Seqirus mentions - Seqirus Media Monitoring - 1st Nov 2017

    View this newsletter in full

Flu shots for seniors

There are two different flu shots – Fluzone High Dose and FLUAD – that are designed specifically for people age 65 and older; FLUAD contains an added ingredient called adjuvant MF59 that also helps create a stronger immune response
31st Oct 2017 - Sun Advocate

Influenza: The Health Minister of NSW announces current preventive ‘not up to the job’ after deadly flu period

There are two flu vaccines which are made to help the elderly. Two of the three manufacturers of the vaccines on the Australian Government’s free influenza immunization program have said proposals that higher rates of this year’s flu virus due to an inexpensive vaccine, are false. Sanofi and Seqirus produce more powerful vaccines, but both did not apply to partake in this year’s immunization program. The third producer, GSK Australian Pharmaceuticals, which produce a less effective vaccine, is quiet about the issue
31st Oct 2017 - Essential Retailer

Flu shots being delivered across the province

Alberta Health Services started administering flu shots throughout the province on Monday. Changes this year include the taking out of FluMist and FluAd from the roster of ways to administer the shot from free clinics. FluAd will still be available at places such as senior’s homes and long-term care homes
30th Oct 2017 - Lac La Biche Post


Seqirus mentions - Seqirus Media Monitoring - 27th Oct 2017

    View this newsletter in full

Flu shots for seniors

There are two different flu shots--Fluzone High Dose and FLUAD--that are designed specifically for people age 65 and older; available in the U.S. since last year, the FLUAD vaccine contains an added ingredient called adjuvant MF59 that also helps create a stronger immune response
26th Oct 2017 - Democrat Tribune


Seqirus mentions - Seqirus Media Monitoring - 26th Oct 2017

    View this newsletter in full

AAP flu policy updated to include new antiviral

The AAP has updated its policy statement on influenza to include a new antiviral medication. The policy Recommendations for Prevention and Control of Influenza in Children, 2017-2018, now provides dosage and administration information for intravenous peramivir, a neuraminidase inhibitor
25th Oct 2017 - AAP News & Journal

Recommendations for Prevention and Control of Influenza in Children, 2017 – 2018


25th Oct 2017 - Pediatrics


Seqirus mentions - Seqirus Media Monitoring - 25th Oct 2017

    View this newsletter in full

Savvy Senior: Flu shots for older adults

There are two different flu shots —Fluzone High Dose and FLUAD — that are designed specifically for people age 65 and older. FLUAD contains an added ingredient called adjuvant MF59 that helps create a stronger immune response
24th Oct 2017 - Press of Atlantic City

'Savy Seniors' one - New Flu Shots, Fluzone High Dose and FLUAD, Specifically For Seniors


24th Oct 2017 - SwiftNary

Flu shots formulated for seniors available


24th Oct 2017 - Star Advertiser

SAVVY SENIOR: Flu shots and the different types for seniors


24th Oct 2017 - Richmond Register

Free $10 gift card with flu shot at Publix Pharmacy

Publix Pharmacy is offering a standard Influenza Trivalent vaccination recommended for everyone 6 months of age or older; Influenza Flucelvax, for those 18 years of age or older and Influenza high-dose for those 65 years of age or older; people receiving the flu shot will be entitled to a free $10 gift card
24th Oct 2017 - Sun Sentinel


Seqirus mentions - Seqirus Media Monitoring - 24th Oct 2017

    View this newsletter in full

Flu shots for seniors

There are two different flu shots – Fluzone High Dose and FLUAD – that are designed specifically for people age 65 and older; FLUAD contains an added ingredient called adjuvant MF59 that also helps create a stronger immune response
23rd Oct 2017 - Huffington Post

Flu vaccine now available in Alberta

Flu immunization clinics are now open all over Alberta province in Canada to provide vaccines, free of charge. FLUAD, a flu vaccine designed to boost the immune response in seniors will not be available at public health clinics but will be administered to those in long term care or supportive living centres, free of charge
23rd Oct 2017 - CTV News Calgary


Seqirus mentions - Seqirus Media Monitoring - 23rd Oct 2017

    View this newsletter in full

Here's What You Actually Need To Know About The Flu Shot

In addition to the standard dose flu shots, there are high-dose shots, recombinant shots, and shots made with an adjuvant. Fluzone is meant for people over 65, Flubok is egg-free, and FLUAD has an immune-boosting supplement
20th Oct 2017 - Buzzfeed.com

Flu Shots for Seniors

There are two different flu shots —Fluzone High-Dose and FLUAD — that are designed specifically for people age 65 and older, offering extra protection beyond what a standard flu shot provides. FLUAD contains an added ingredient called adjuvant MF59 that also helps create a stronger immune response
20th Oct 2017 - Daily Citizen

Savvy Senior: Flu shots for seniors


22nd Oct 2017 - Sentinel Source

Flu shots for seniors offer extra protection but can cause side effects


22nd Oct 2017 - New Jersey Herald


Seqirus mentions - Seqirus Media Monitoring - 20th Oct 2017

    View this newsletter in full

Credit Suisse: CSL Limited shares are set to outperform

Analysts at Credit Suisse have slapped an outperform rating on shares in CSL; Seqirus, CSL’s influenza vaccine division is growing revenue and is on the path to profitability according to management
19th Oct 2017 - Motley Fool Australia

Flu shots for seniors

There are two different flu shots – Fluzone High Dose and FLUAD – that are designed specifically for people age 65 and older; FLUAD contains adjuvant MF59 that also helps create a stronger immune response. In a 2012 Canadian observational study, FLUAD was 63 percent more effective than a regular flu shot
19th Oct 2017 - Williston Observer

Is the CSL Limited CEO paid too much?

CSL shareholders were keen to resolve an ongoing dispute about executive pay at the company’s AGM but some weren’t happy after the CEO enjoyed another pay increase despite remuneration concerns raised last year. David Anstice, Chairman of CSL’s Human Resources and Remuneration Committee, said Mr Perreault and his team delivered above target earnings growth, sector leading growth in plasma collection volumes, launched new products, ensured the Seqirus strategic plan remains on track, and secured an entry strategy into China
19th Oct 2017 - Motley Fool Australia


Seqirus mentions - Seqirus Media Monitoring - 19th Oct 2017

    View this newsletter in full

CSL moves to change CEO pay structure to avoid second strike from shareholders

CSL chairman John Shine says 88 per cent of shareholders have agreed to vote in favour of the company's revamped remuneration report after an investor backlash over excessive executive pay.
18th Oct 2017 - The Sydney Morning Herald

CSL pay overhaul calms investors


18th Oct 2017 - The Australian

CSL rejigs CEO pay to appease shareholders


18th Oct 2017 - Illwarra Mercury

Savvy Senior: Flu shots for seniors

There are two different flu shots — the Fluzone High Dose and FLUAD — that are designed specifically for people age 65 and older. These FDA approved vaccines are designed to offer extra protection beyond what a standard flu shot provides, which is important for older adults
18th Oct 2017 - Logan Daily

Several flu clinics available in coming weeks

In Canada, influenza immunizations will be available at Alberta Health Services clinics within a week; only Fluzone will be available free of charge. FLUAD, designed to boost the immune response in seniors, will only be available to seniors living in long-term care or supportive living
18th Oct 2017 - Medicine Hat News


Seqirus mentions - Seqirus Media Monitoring - 16th Oct 2017

    View this newsletter in full

A flu vaccine with MF59 enhancer can better protect children between six and 24 months from influenza viruses than the conventional vaccines

A flu vaccine with MF59 enhancer can better protect children between six and 24 months from influenza viruses than the conventional vaccine, according to a Phase III study presented by researchers from the University of Tampere Medical School in Finland at an international conference in Riga. "For older children, there was no additional benefit," said Timo Vesikari of the University of Tampere about the study he carried out together with scientists from Finland, the US, the Philippines and Seqirus
11th Oct 2017 - aertzeblatt.de


Seqirus mentions - Seqirus Media Monitoring - 13th Oct 2017

    View this newsletter in full

VaccinatioNCelebration offers NC-made flu shots at NC Biotech Center

The North Carolina Biotechnology Center is hosting the second annual VaccinatioNCelebration flu shot clinic on Oct. 17, 2017, to highlight North Carolinians’ production of the newest generation of flu vaccine. Flucelvax Quadrivalent is made at the $1 billion Seqirus biomanufacturing facility in Holly Springs from a cell culture process rather than the traditional growing of the key component in chicken eggs
12th Oct 2017 - Wral Techwire.com


Seqirus mentions - Seqirus Media Monitoring - 11th Oct 2017

    View this newsletter in full

Get ready for flu season

Arizona already has regional flu, according to the CDC, with 97 cases reported within the University of Arizona campus. Two new quadrivalent flu vaccines have been licensed: one inactivated influenza vaccine (“Afluria Quadrivalent” IIV) and one recombinant influenza vaccine (“Flublok Qudrivalent” RIV)
10th Oct 2017 - Payson Roundup


Seqirus mentions - Seqirus Media Monitoring - 10th Oct 2017

    View this newsletter in full

7 ways to help tame kids' fear of flu shots

For the second year in a row, the CDC is telling doctors not to give patients FluMist, and that’s a problem for kids and adults who are scared of needles. There is a new needle-free vaccine available for children as young as 5 years old: Afluria, which is administered under high pressure directly through the patient’s skin
9th Oct 2017 - The Pueblo Chieftain

7 ways to help tame kids' fear of flu shots


8th Oct 2017 - Herald Times Online


Seqirus mentions - Seqirus Media Monitoring - 9th Oct 2017

    View this newsletter in full

Vaccine more effective when many get it

Fluad is one of the vaccines recommended by the CDC. Research shows that older adults who received Fluad were less likely to develop symptomatic influenza illness or be hospitalized for influenza or pneumonia than those who received a standard-dose trivalent vaccine
7th Oct 2017 - kpc news.com

CSL hopes acquisition will fix blood supply problem in China

CSL has bought a blood collection company to fix its supply problems in China, as part of its ambition to be the country’s biggest plasma collector. “The reason for the acquisition goes back to the regulations. It’s just you can’t access the market unless you have a company here,” said Paul Perreault, CSL’s chief executive
7th Oct 2017 -

Mobile Flu Clinic To Visit The Glastonbury Apple Harvest Festival

The health department, in partnership with Health Choices Program, will host a Fastvax mobile flu clinic on at the Apple Harvest Festival in order to reach as many people as possible; for those 4-17 years old, Flucelvax (egg and preservative free) and Fluarix will be available
6th Oct 2017 - Hartford Courant


Seqirus mentions - Seqirus Media Monitoring - 6th Oct 2017

    View this newsletter in full

Holly Springs company on the forefront of new flu shot technology

Seqirus is leading the world in producing a new type of flu vaccine. "We're charged with a mission for keeping healthy people healthy," said Chad Salisbury, director of supply chain and strategy with Seqirus. Seqirus became the first influenza vaccine company to produce a cell-based influenza vaccine on a commercial scale
5th Oct 2017 - wral.com

DDF 2017: Choosing a CRO, and the implications of new R2 regulations

Karen Gardner, senior director of clinical development at Seqirus, talks about the fact that “small biotechs spend a lot less money than the bigger biotechs, but they still get the delivery outcomes.” When choosing a CRO, quality does matter, she adds
5th Oct 2017 - Fierce Biotech

Liverpool City Region LEP strengthens board

Seven new private sector members have been appointed to the Board of the Liverpool City Region Local Enterprise Partnership (LEP) to help drive the City Region’s economic growth over the next three years. Among the new members is Laura O’Brien, VP & Site Head at Seqirus
5th Oct 2017 - bqlive.co.uk

Flu shot season is here

Among the news for the 2017/2018 flu season is that two new quadrivalent flu vaccines have been licensed: one inactivated influenza vaccine (“Afluria Quadrivalent” IIV) and one recombinant influenza vaccine (“Flublok Qudrivalent” RIV)
5th Oct 2017 - Marietta Times


Seqirus mentions - Seqirus Media Monitoring - 5th Oct 2017

    View this newsletter in full

BioCryst announced that interim results from a clinical trial of a single IV dose of RAPIVAB for the treatment of pediatric influenza will be presented at IDWeek 2017, taking place in San Diego, October 4-8, 2017

BioCryst announced that interim results from a clinical trial of a single IV dose of RAPIVAB for the treatment of pediatric influenza will be presented at IDWeek 2017, taking place in San Diego, October 4-8, 2017
4th Oct 2017 - Globenewswire.com

BioCryst Announces RAPIVAB (peramivir injection) and Galidesivir Presentations at IDWeek 2017


4th Oct 2017 - Pharmiweb.com

BioCryst Announces RAPIVAB (peramivir injection) and Galidesivir Presentations at IDWeek 2017


4th Oct 2017 - Yahoo Finance

BioCryst Announces RAPIVAB (peramivir injection) and Galidesivir Presentations at IDWeek 2017


4th Oct 2017 - Infotech Spotlight

BioCryst Pharma to present new data on Rapivab and antiviral galidesivir at IDWeek


4th Oct 2017 - Seeking Alpha

‘Miserable’ flu season expected

Flu patients sometimes need treatment with prescription medications called anti-viral drugs, including Tamiflu, Rapivab or Relenza, which work best when taken within 48 hours of the start of the flu symptoms
3rd Oct 2017 - TC Times.com


Seqirus mentions - Seqirus Media Monitoring - 4th Oct 2017

    View this newsletter in full

Prevent influenza by getting flu shot

In 2015, the U.S. FDA approved the use of a new seasonal flu vaccine for adults 65 years and older. The vaccine contains an adjuvant to create a stronger immune response to the vaccination: FLUAD, is available during the 2017-18 season
3rd Oct 2017 - Columbus Telegram

Is your child scared of shots? Are you? Here are 7 things you can do to tame the fear

For the second year in a row, the CDC is telling doctors not to give patients FluMist, and that’s a problem for kids and adults who are scared of needles; there is a new needle-free vaccine available for children as young as 5 years old, Afluria, administered under high pressure directly through the patient’s skin
3rd Oct 2017 - News Observer.com


Seqirus mentions - Seqirus Media Monitoring - 3rd Oct 2017

    View this newsletter in full

Prepare for a Rocky Flu Season

For those 65 and up, experts recommend two stronger vaccines: Fluad, made using an adjuvant, which helps create a stronger immune response in the body and first became available last year, and Fluzone High-Dose, which contains four times the amount of antigen as the regular vaccine
2nd Oct 2017 - msn.com

Optimal Influenza Treatment: Understand Influenza Testing

Antiviral treatment should be started within 24 hours if a patient is suspected of having the flu, and prescribers can use one of a number of FDA-approved agents (amantadine and rimantadine for influenza A; oseltamivir phosphate, peramivir, and zanamavir for circulating influenza viruses) to treat patients
2nd Oct 2017 - Pharmacy Times


Seqirus mentions - Seqirus Media Monitoring - 2nd Oct 2017

    View this newsletter in full

If you get the flu, this drug can save your life. Now it’s approved for your kids

Rapivab was developed for the U.S. government with $235 million in federal funding, and is one of the critical drugs maintained in the Strategic National Stockpile to protect the public during pandemics and bio-terror attacks. The medication was approved this month for patients aged 2- to 18-years old by the U.S. FDA
29th Sep 2017 - News Observer


Seqirus mentions - Seqirus Media Monitoring - 29th Sep 2017

    View this newsletter in full

The thinking process behind biopharma companies’ outsourcing management

Among the biopharma executives making presentations at this year’s Drug Development Forum was Karen Gardner, senior director of clinical development operations at CSL’s vaccines subsidiary Seqirus. She says entering into an outsourcing partnership is buying a multidimensional service. “It’s a component of people, of process and of work that needs to be done and when”
28th Sep 2017 - Fierce Biotech

Seasonal Influenza: What is the most effective vaccine?

New results presented at the European Scientific Working Group on Influenza (ESWI) Congress in Riga indicate that the adjuvant vaccine produces a better immune response against influenza in the population over 65 than the non-adjuvanted vaccine
28th Sep 2017 - Sanihelp.it

U.S. Health Officials Urge Annual Influenza Vaccination for All

The NFID, along with public health and medical organizations, urged the public to follow the CDC recommendation that everyone age six months and older be vaccinated against influenza. Three FDA-approved influenza antiviral drugs are also recommended for use in the U.S.: oseltamivir (generic version or Tamiflu), zanamivir (Relenza), and peramivir (Rapivab)
28th Sep 2017 - PR Newswire.com

Health Officials Urge Annual Influenza Vaccination for All


28th Sep 2017 - Infection Control Today


Seqirus mentions - Seqirus Media Monitoring - 28th Sep 2017

    View this newsletter in full

Influenza; list of vaccines authorized by the Aifa for the 2017/2018 season

The Italian Drug Agency (AIFA) has released the list of influenza vaccines for the 2017/2018 season, including Afluria, Agrippal S1, Fluad and Influpozzi by Seqirus; Batrevac and Influvac S by BGP Products (Mylan group); Fluarix Tetra by GlaxoSmithKline, Vaxigrip and Vaxigrip Tetra by Sanofi Pasteur
27th Sep 2017 - Blasting News Italy

Changes to available vaccines as influenza season begins

Alberta has purchased 1.6 million doses of flu vaccine for the 2017/18 season, enough to immunize 35 per cent of the population at a cost of $12.1 million.Only one type of influenza vaccine will be offered free of charge — Fluzone — as an injection. FLUAD will not be available except to seniors living in long-term care or supportive living
27th Sep 2017 - Medicine Hat News

Flu shots available in Alberta starting Oct. 23; AHS not offering nasal spray


26th Sep 2017 - Global News

Free flu shots start October 23rd


26th Sep 2017 - My Grande Prairie Now.com

Fini le vaccin intranasal gratuit en Alberta


27th Sep 2017 - Radio Canada

What’s new with the flu

Among the new recommendations for the 2017-2018 flu season is that the trivalent formulation of Afluria is recommended for people 5 years and older (from 9 years and older) in order to match the Food and Drug Administration packaging
26th Sep 2017 - TC Palm.com


Seqirus mentions - Seqirus Media Monitoring - 27th Sep 2017

    View this newsletter in full

Influenza; list of vaccines authorized by the Aifa for the 2017/2018 season

The Italian Drug Agency (AIFA) has released the list of influenza vaccines for the 2017/2018 season, including Afluria, Agrippal S1, Fluad and Influpozzi by Seqirus; Batrevac and Influvac S by BGP Products (Mylan group); Fluarix Tetra by GlaxoSmithKline, Vaxigrip and Vaxigrip Tetra by Sanofi Pasteur
26th Sep 2017 - About Pharma.com

In Our Opinion: Don't put off getting your flu shot this year

This year, there is an enhanced vaccine for senior citizen: the FLUAD shot contains four times the amount of antigen as the regular one and boosts immune response following vaccination. A study by the CDC showed that it reduced cases of the flu by 24 percent for seniors compared to the standard vaccine
27th Sep 2017 - Daily Star.com

A Flu Med with Meager Benefits

With the flu season threatening, the FDA has just approved an IV treatment for the flu for children as young as 2 years old. Rapivab (peramivir) was first approved for adults by the FDA in late 2014. It joins Tamiflu and Relenza (zanamivir) as questionably useful drugs that shorten a bout with the flu by a scant 12 to 22 hours
26th Sep 2017 - Med Shadow

Do you know what is contained in a vaccine and why?

An explanation of the additives to be found in vaccines; Fluad was licensed by the FDA in November 2015 as the first seasonal influenza vaccine containing a novel adjuvant. Fluad is licensed for people 65 years of age or older but may become available for children
26th Sep 2017 - AAP News & Journal

Alberta won't offer nasal spray this flu season

Alberta Health Services held a news conference where health officials announced Fluad, which is for seniors, and FluMist, used on children, will no longer be available. Only seniors living in long-term care or in supported living facilities will have access to Fluad
26th Sep 2017 - 660news.com


Seqirus mentions - Seqirus Media Monitoring - 26th Sep 2017

    View this newsletter in full

Flu is a tragic illness how can we get more people to vaccinate?

Some parents have concerns about the safety of the flu vaccine; Australians were spooked by a 2010 incident when there was a temporary suspension of flu vaccine for children under five after reports of an increase in the rate of convulsions in children. The one vaccine found to be the cause (BioCSL/Seqiris Fluvax) is no longer approved for use in children younger than
25th Sep 2017 - Australian Journal of Pharmacy

Flu season should not be taken lightly — get vaccinated

It’s time to get flu shots. For people 65 years and older, two vaccines are available: a high-dose version that contains four time the amount of immune-response agent as a regular flu shot, and the Fluad vaccine aimed at boosting one’s immune response to vaccination
25th Sep 2017 - Chicago Sun Times


Seqirus mentions - Seqirus Media Monitoring - 25th Sep 2017

    View this newsletter in full

How can we get more people to vaccinate against flu?

Some parents have concerns about the safety of the flu vaccine; Australians were spooked by a 2010 incident when there was a temporary suspension of flu vaccine for children under five after reports of an increase in the rate of convulsions in children. The one vaccine found to be the cause (BioCSL/Seqiris Fluvax) is no longer approved for use in children younger than five
22nd Sep 2017 - Medical Express

The flu will kill more people in Australia

Australia’s Health Ministry is considering adopting a more powerful form of the flu vaccine to cope with the epidemic. Health authorities have begun negotiations with Seqirus to market the FLUAD vaccine, which will increase the effectiveness of the influenza vaccine
24th Sep 2017 - Neokosmos.com

Routine use of new type of flu vaccine in older people 'could prevent 1,700 deaths'

If older people were switched from a conventional non-adjuvanted vaccine currently used in the UK immunisation programme to an adjuvanted trivalent influenza vaccine (aTIV), 195,600 cases of influenza could be prevented, according to estimations by researchers; Seqirus announced last month that it could supply 10 million doses of Fluad in the UK for the 2018-19 flu season
22nd Sep 2017 - Nursing Times

Flu experts: Hoping for milder season, more effective vaccine

The CDC said some flu shots will protect against three flu viruses, while others protect against four flu viruses. There are two new flu vaccines: an inactivated version known as Afluria and Flublok. The CDC also has approved for the first time a cell-based candidate vaccine virus for flu vaccine production in the Northern Hemisphere
24th Sep 2017 - Journal Now

Flu is a tragic illness. How can we get more people to vaccinate?


22nd Sep 2017 - The Conversation.au

VaccinatioNCelebration Offers NC-Made Flu Shots at NCBiotech Oct. 17

The North Carolina Biotechnology Center is hosting the second annual VaccinatioNCelebration flu shot clinic all day Tuesday, Oct. 17, 2017, to highlight North Carolinians’ production of the newest generation of flu vaccine. The vaccine, Flucelvax Quadrivalent, is made at the $1 billion Seqirus biomanufacturing facility in Holly Springs from a cell culture process rather than the traditional growing of the key component in chicken eggs.
18th Sep 2017 - North Carolina Biotechnology Center


Seqirus mentions - Seqirus Media Monitoring - 20th Sep 2017

    View this newsletter in full

Millions of flu vaccines uniquely made in Holly Springs

Flu season begins in October and at the Holly Springs site of Seqirus, their work is already done. Over the last six months, researchers developed 21 million doses of flu vaccines which are now being distributed to hospitals, doctors' offices, pharmacies, and government agencies
19th Sep 2017 - abc11.com

$4.92M gift to Penn State for industrial biotechnology education, research

CSL has committed $4.92 million to Penn State over the next six years to create the multidisciplinary Center of Excellence in Biotechnology, and to revitalize the Shared Fermentation Facility, an engine for collaboration and innovation in biological training and research on the University Park campus
19th Sep 2017 - Penn State News

CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State


19th Sep 2017 - PR Newsire.com

CSL: Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT for People Five Years of Age and Older in the U.S

Seqirus announced that the U.S. Food and Drug Administration has approved AFLURIA QUADRIVALENT for use in people five years of age and older
19th Sep 2017 - 4-traders.com


Seqirus mentions - Seqirus Media Monitoring - 18th Sep 2017

    View this newsletter in full

Adjuvanted vaccine could improve flu protection and slash GP workload

Lead author of the ESWI study Dr James Mansi said: ‘Influenza in older adults is often particularly severe, due in part to their ageing immune systems which mean that vaccines don’t produce an optimal immune response. ‘These results predict that the immunisation of older adults with aTIV rather than a standard influenza vaccine would results in improved protection against influenza in the over-65s.
14th Sep 2017 - GP Online

CSL’s vaccine wins FDA approval

CSL has announced that Seqirus has received FDA approval of their influenza vaccine for people five years of age and older in the U.S. The FDA approved Afluria Quadrivalent, extending the company’s portfolio of influenza vaccine offerings
15th Sep 2017 - Finance News Network

Vaccine against four strains of influenza approved for pediatric use in the USA


15th Sep 2017 - Pharma Letter.com

Flu Season Is Around the Corner: What You Need to Know

A round-up of flu related information for pharmacists, including which vaccines are indicated for which patients; Fluad and Fluzone High-Dose are indicated for patients 65 and older. However, this group may be vaccinated with standard dose vaccines
15th Sep 2017 - Pharmacy Times